


Available online at www.sciencedirect.com

SciVerse ScienceDirect

www.elsevier.com/locate/brainres

Brain Research



Research Report

An update on the cognitive impact of clinically-used hormone therapies in the female rat: Models, mazes, and mechanisms

J.I. Acosta^{a,c}, R. Hiroi^{a,c}, B.W. Camp^{a,c}, J.S. Talboom^{b,c}, H.A. Bimonte-Nelson^{a,c,*}^aDepartment of Psychology, Arizona State University, Tempe, AZ 85287, USA^bSchool of Life Sciences, Arizona State University, Tempe, AZ 85287, USA^cArizona Alzheimer's Consortium, USA

ARTICLE INFO

Article history:

Accepted 9 January 2013

Available online 16 January 2013

Keywords:

Menopause

Cognition

Memory

Hormone loss

Hormone therapy

Estrogen

Progestogen

Androgen

ABSTRACT

In women, ovarian hormone loss associated with menopause has been related to cognitive decline. Hormone therapy (HT) may ameliorate some of these changes. Understanding the cognitive impact of female steroids, including estrogens, progestogens, and androgens, is key to discovering treatments that promote brain health in women. The preclinical literature has presented elegant and methodical experiments allowing a better understanding of parameters driving the cognitive consequences of ovarian hormone loss and HT. Animal models have been a valuable tool in this regard, and will be vital to future discoveries. Here, we provide an update on the literature evaluating the impact of female steroid hormones on cognition, and the putative mechanisms mediating these effects. We focus on preclinical work that was done with an eye toward clinical realities. Parameters that govern the cognitive efficacy of HT, from what we know thus far, include but are not limited to: type, dose, duration, and route of HT, age at HT initiation, timing of HT relative to ovarian hormone loss, memory type examined, menopause history, and hormone receptor status. Researchers have identified intricate relationships between some of these factors by studying their individual effects on cognition. As of late, there is increased focus on studying interactions between these variables as well as multiple hormone types when administered concomitantly. This is key to translating preclinical data to the clinic, wherein women typically have concurrent exposure to endogenous ovarian hormones as well as exogenous combination HTs, which include both estrogens and progestins. Gains in understanding the parameters of HT effects on cognition provide exciting novel avenues that can inform clinical treatments, eventually expanding the window of opportunity to optimally enhance cognition and brain health in aging women.

This article is part of a Special Issue entitled Hormone Therapy.

© 2013 Elsevier B.V. All rights reserved.

*Corresponding author at: Arizona State University, Department of Psychology, P.O. Box 871104, Tempe, AZ 85287, USA.

Fax: +1 480 965 8544.

E-mail address: bimonte.nelson@asu.edu (H.A. Bimonte-Nelson).

0006-8993/\$ - see front matter © 2013 Elsevier B.V. All rights reserved.

<http://dx.doi.org/10.1016/j.brainres.2013.01.016>

1. Ovarian hormones and cognition in the rodent: Historical context and clinical implications

In 1927, A.S. Parkes published a monograph in *The Proceedings of the Royal Society of Medicine* entitled “Internal Secretions of the Ovary”, in which it is stated that, “The solution of the type of problem found in studying the internal secretions of the ovary is most satisfactorily sought by experiment, and since the lower mammals have to be used for this type of work, it is on their reactions that our knowledge of ovarian activity mainly depends. At the same time, however, ovarian activity in the human subject must obey similar laws, and with the aid of clinical observations, experimental work on the lower mammals may be made to throw much light on the problems associated with the human species” (Parkes, 1927, page 45). It is notable that even now, some eight decades later, researchers studying “internal secretions of the ovary” employ similar tenets of utilizing rodent models to understand the multiple effects that these hormones have on body systems and functions. Today we typically refer to “internal secretions of the ovary” as ovarian steroid hormones. Early researchers seeking to learn the functions of the internal secretions of the ovary observed, via experimental evaluations, that the ovary is essential for development of accessory reproductive organs, the estrous cycle, sustaining pregnancy, and mammary gland development (Parkes and Bellerby, 1926). Other studies led to the discovery that these secretions are involved in more than reproductive-related morphology and function; they are also involved in reproductive behaviors (Beach, 1947). Subsequent research has now shown that gonadal steroids impact many non-reproductive actions and functions in the brain as well, including learning and memory, and several of its postulated mechanisms. For many researchers, the hope is to translate findings to a genuine clinical impact on women's health.

In animal models and humans, the female steroids estrogens, progestogens and androgens have each been shown to impact cognition. To evaluate the cognitive effects of female steroid hormones in humans, researchers have been creative in their assessments and have reported effects across menopause transition stages (Luetters et al., 2007), with sex-reassignment operations and concomitant sex hormone treatment (Gomez-Gil et al., 2009), and with hormone therapy (HT) before versus after surgery in surgically menopausal women (Sherwin, 2006). Animal models have been used to test the cognitive effects of steroid hormones. In animal models, the traditional procedure is to remove the major source of endogenous synthesis and release, the testes in the male (gonadectomy, or GDX) or the ovaries in the female (ovariectomy, or Ovx), then administer the exogenous steroid of question as a treatment regimen after surgery.

Notably, within the last decade, research in both the animal and human literature evaluating the potential influence of gonadal hormones on brain health and function during aging has increased in breadth and depth. Much of this elevated interest is largely because of the recent discussion and debate about whether HTs impact normal aging and/or Alzheimer's disease (AD). These reports include,

but are not limited to: a meta-analysis showing that estrogen-containing HTs decreased the risk of AD by 29% (Yaffe et al., 1998); placebo-controlled studies showing estrogens enhanced memory or improved dementia scores in female AD patients (Asthana et al., 1999, 2001; Ohkura et al., 1994, 1995); a study showing that menopause exacerbated age-related cognitive changes in several domains, including visuospatial abilities (Halbreich et al., 1995); and then more recently, the outcome of the Women's Health Initiative (WHI) studies showing null or detrimental effects on cognition or dementia from the most commonly used HTs (for discussion, see Coker et al., 2010; Henderson, 2008; Maki and Henderson, 2012; Sherwin and Henry, 2008).

A major factor propelling research in women's health is that the life expectancy of women has significantly increased from an average of 54 years, to about 80 years (Singh et al., 1996). Since women are living longer, but age of spontaneous menopause has remained stable, women are now living approximately one-third of their lives in a hypo-estrogenic menopausal state (Amundsen and Diers, 1970, 1973; Sherwin, 2003). This realization has resulted in an increased interest in understanding the effects of ovarian hormone loss and subsequent HT administration. Emerging findings are now indicating that multiple parameters impact the extent, and even in some cases the direction, of cognitive effects of hormone loss and administration. Findings show the broad impact of gonadal hormone effects on brain functions such as learning and memory, and underscore the rich effects that ovarian hormones have on brain plasticity.

Here, we review recent findings on the impact of gonadal hormones during cognitive aging. We discuss this work in the context of landmark gonadal hormone-related discoveries that have provided the framework to guide a path to healthy cognitive aging. Evidence regarding hormone loss and parameters involving treatment optimization has emerged from both preclinical and clinical realms. Preclinical animal models have been widely used because they allow methodical experimental control of factors likely influencing outcome in clinical studies such as age, duration of hormone loss or treatment, specific type and dose of hormone manipulated, socioeconomic status, and education. Here, we review literature focusing on the female, spanning the activational effects of estrogens, progestogens, and androgens. We will discuss effects on cognition, brain health, and the neuromechanisms possibly mediating these effects. Further, because spatial cognition has been the focus of the majority of the preclinical research in this area, we will focus on spatial cognition, and review the memory types most commonly measured. We will discuss ovarian hormones, as well as synthetic and naturally-derived hormones included in various HT regimens. Ovarian hormones are endogenous and originating from the ovaries of the organism, and hormones from HTs are exogenous and originating from outside of the organism. Thus, the term “ovarian hormone” does not accurately encompass hormones that are exogenously administered and not released endogenously, such as many of those in HTs. For parsimonious discussion, we refer collectively to both endogenous ovarian-derived hormones from the subject, and administered HT hormones, as “female steroid” hormones. A summary of female steroid hormone exposure throughout the lifespan,

and effects on cognition with associated putative mechanisms, is illustrated in Fig. 1. Reference ID numbers in this figure are elucidated in Table 1. In addition, we also summarize the spatial memory effects of female steroids either administered independently (Table 1), or estrogens administered concomitantly with progestogens (Table 2), in middle-aged and aged female rats.

2. Operationally defining and testing memory effects of female steroids in the preclinical setting

When studying learning and memory in the rodent model, it is vital to acknowledge the multiple parameters involved in the process of quantifying cognition in order to properly interpret data. Within the specific domain of spatial navigation, rodents learn to navigate through a novel environment so that routes to the target eventually become familiar, and associations are formed from cues in the environment to aid overall navigation. Spatial learning and memory involves the ability to navigate effectively through an environment, acquiring, integrating, and retaining environmental features such as landmarks and other prominent cues; spatial abilities

depend upon medial temporal lobe structures such as the hippocampus (Barnes, 1998).

Being able to differentiate and test various types of spatial memory is vital to successful translational research. Many experimental tests of rodent spatial memory aim to assess spatial working memory, a form of short-term memory which requires a subject to retain spatial information which must be updated and is useful for only a short period of time (trial-specific information, Baddeley and Hitch, 1974). Working memory requires manipulation of information kept “on-line”; in fact, the late Dr. Patricia Goldman-Rakic cleverly and accurately referred to working memory as “working with memory” (Goldman-Rakic, 1987). Working memory is affected by normal aging, revealing a memory decline that becomes more severe as task difficulty increases (Balota et al., 2000). In animals, age-related spatial deficits become more pronounced as memory demand increases as well. This has been shown for age-associated interference-related deficits (Lebrun et al., 1990) and for memory capacity deficits (Aggleton et al., 1989; Bimonte-Nelson et al., 2003, 2004b; Bimonte et al., 2003). In general, working memory is distinguished from reference memory, which is necessary to remember information that remains constant over time (task-specific information, for discussion see Olton et al., 1979).




Fig. 1 – Female steroid hormones can impact the brain and cognition throughout the lifespan. In women, female steroid hormone exposure encompasses both endogenous and exogenous exposures in a lifetime. Endogenous hormone exposure occurs throughout life, including during the prenatal environment, birth, puberty, and menopause, and exogenous hormone exposure occurs from contraceptives during reproductively active years and/or hormone therapy (HT) during menopause. Organizational and activational effects on the brain interact and ultimately impact cognitive outcome. Female steroid-induced effects on cognitive outcome depend on many factors. Putative neurobiological mechanisms underlying hormone-induced alterations in cognition include those listed in the brain schematic in the figure. Regarding research investigating the cognitive effects of various types of HT in middle-aged and aged rats, the plus sign (+) denotes positive effects on cognition and the minus (–) sign denotes detrimental effects on cognition. The numbers under the plus and minus signs refer to the corresponding publication/Reference ID# listed in Table 1. List of abbreviations: CEE (conjugated equine estrogen); E1 (estrone); E2 (estradiol); P4 (progesterone); MPA (medroxy-progesterone acetate); DHT (dihydrotestosterone); Andro (androstenedione).

Table 1 – Effects of female steroid administration on spatial memory in middle-aged and aged female rats. Only hormones given independently are reported here.

Hormone	Reference ID#	Dose	Regimen	Behavior Examined	Effect on cognition	Reference
CEE	1	10µg injection	Cyclic	MWM, DMS	+	Acosta et al., 2009
		20µg injection	Cyclic	MWM, DMS	+	
		30µg injection	Cyclic	MWM, DMS	+	
	2	12µg pumps	Tonic	DMS, MWM	-	Engler-Chiurazzi et al., 2011
		24µg pumps	Tonic	DMS	+	
		36µg pumps	Tonic	DMS, WRAM	+	
E1	3	8.0µg/day pumps	Tonic	DMS	-	Engler-Chiurazzi et al., 2012
E2	4	0.25mg or 0.50mg/60 day release pellet	Tonic	MWM	+	Talboom et al., 2008
	5	10% estradiol benzoate capsule Low- 0.5 cm	Tonic	MWM	+	Foster et al., 2003
		10% estradiol benzoate capsule High- 1 cm	Tonic	MWM	+	
	6	25% E2 implant	Tonic	MWM	+	Markham et al., 2002
		16.67µg E2/kg in .5cc injections	Acute	MWM	+	
	7*	25% E2 implant in a 5 mm silastic capsule	Tonic	DMP	+	Gibbs et al., 2000
	8	.25mg, 60 day release pellet	Tonic	MWM	+	Bimonte-Nelson et al., 2006
		.50mg, 60 day release pellet	Tonic	MWM	+ Only on Day 1 Trial 2	
		10µg injection	Cyclic	MWM	+	
	9*	10µg injection + 3mm E2 pellet	Cyclic +Tonic	DNMP, MWM	+	Markowska et al., 2002
	10*	3mm E2 pellet	Tonic	T-maze active avoidance	+	Savonenko et al., 2003
P4	12	(3) P4 pellets of 200mg, 90 day release	Tonic	WRAM	-	Bimonte-Nelson et al., 2004
	13	21mg pumps	Tonic	WRAM	-	Braden et al., 2010
MPA	14	21mg pumps	Tonic	WRAM, MWM	-	Braden et al., 2010
	15	3.5mg injection	Cyclic	WRAM, MWM	-	Braden et al., 2011
Andro	16	8mg/kg	Tonic	WRAM, DMS, MWM	-	Camp et al., 2012

Legend: Morris water maze (MWM), Water radial arm maze (WRAM), Delayed matched-to-sample plus maze (DMS), Delayed non-match to position (DNMP). The reference ID# refers to the numbers listed in Fig. 1.

(+) denotes a positive effect on cognition.

(-) denotes a negative effect on cognition.

17β-estradiol (E2).

Progesterone (P4).

Medroxyprogesterone acetate (MPA).

Androstenedione (Andro).

*Indicates that a turn strategy can be used for successful performance; animals are not “encouraged” to use space.

Table 2 – Effects of combination estrogens+progestogens administration on spatial memory in middle-aged and aged female rats.

<i>Hormone</i>	<i>Dose</i>	<i>Regimen</i>	<i>Behavior Examined</i>	<i>Effect on cognition</i>	<i>Reference</i>
E2 + P4	10µg injection E2 + 500µg injection P4	Cyclic E2 + Cyclic P4	*DMP	+	Gibbs et al., 2000
	0.25mg E2 pellet (60 day release) + Two 200mg P4 pellets (90 day release)	Tonic E2 + Tonic P4	MWM	- (relative to tonic E2 alone, not vehicle)	Bimonte-Nelson et al., 2006
	10 µg injection E2+ 2 pellets of 200mg P4, (90 day release)	Cyclic E2+ Tonic P4	MWM	- (relative to cyclic E2 alone, not vehicle)	
	25% E2+ 75% and 100% P4 implant	Tonic E2+ Tonic P4	MWM	+	Markham et al., 2002
	47µg/kg/day E2 in drinking water + 40mm P4 implant	Tonic E2+ Tonic P4	MWM	+ (relative to tonic E2 + MPA, not vehicle)	Lowry et al., 2010
E2+ MPA	47µg/kg/day E2 in drinking water + 1.5mg 90 day release MPA pellet	Tonic	MWM	- (relative to cyclic E2, tonic E2, & tonic E2+P4, not vehicle)	Lowry et al., 2010
	47 µg/kg/day E2 in drinking water + 1.5mg 90 day release MPA pellet	Tonic	*T-maze alternation, delayed alternation	+ (relative to vehicle, cyclic E2, & tonic E2)	Chisholm et al., 2012

Legend: Morris water maze (MWM), Water radial arm maze (WRAM), Delayed matched-to-sample plus maze (DMS), Delayed non-match to position (DNMP). The reference ID# refers to the numbers listed in Fig. 1.

(+) denotes a positive effect on cognition.

(-) denotes a negative effect on cognition.

17β-estradiol (E2).

Progesterone (P4).

Medroxyprogesterone acetate (MPA).

*Indicates that a turn strategy can be used for successful performance; animals are not “encouraged” to use space.

3. Activational versus organizational effects of hormones: Perspectives for discussion herein

Gonadal steroid hormone actions are traditionally referred to as having *organizational effects*, operationally defined in the traditional sense as occurring early in development and having permanence, or as having *activational effects* which occur later in development, are transitory, and therefore depend on presence of the hormone at the time of assessment. For example, sex differences in neuroanatomy have been traditionally thought to reflect the permanent organizing effects of steroids present during early development. Activational effects have been thought to activate the underlying organized neural substrate. The expression of many sexually dimorphic behaviors (for example, sexual behaviors in rodents) depend on the presence of circulating hormones; indeed, exogenous administration of sex steroids can induce these

behaviors as long as the hormone remains present. Notably, organizational and activational effects work together; as an example, while early hormonal exposure plays a significant role in organizing brain substrates underlying sexually differentiated behaviors, most of these effects are realized only when activational exposure ensues (e.g., Beatty, 1992). Endogenous gonadal hormones or exogenous hormone administration in adulthood can therefore impact behavioral phenomena that were organized early in development. This interactive model demonstrates that activating (or circulating) hormones are acting upon a neural substrate that has been differentiated, and therefore, a “male” versus “female” brain is unlikely to respond to the same circulating hormones in the same way (e.g., Beatty and Beatty, 1970). Accumulating evidence has, however, blurred this traditional organizational/activational dichotomy, with the temporal distinction being called into question. For example, estrogenic activation of sexual behavior in female rat pups has been seen as young as 6 days of age

(Williams, 1987), and non-transient changes in brain morphology following post-pubertal hormone manipulations have been noted (Bimonte et al., 2000a, 2000b, 2000c; Bloch and Gorski, 1988; Pappas et al., 1979; Rodriguez-Sierra, 1986). It has therefore been suggested that the newer organizational/activational distinction should primarily depend on whether the induced effects are permanent or transient, regardless of when they occur during the lifespan (e.g., see Arnold and Breedlove, 1985; Fitch and Denenberg, 1998; Stewart and Kolb, 1988 for discussion).

How do we discuss new findings of ovarian hormone effects on the brain and its function within the context of the organizational/activational dichotomy? While defining these effects as organizational or activational does not necessarily change how we interpret the resulting experimental data per se, it is ideal (and some hormone researchers may say, necessary) to acknowledge the findings within the context of this long-held tenet. There is rich neurophysiological and neurochemical plasticity in the female brain, including brain regions known to subserve learning and memory, suggesting that cognitive brain regions are sensitive to ovarian hormone fluctuation (Becker and Cha, 1989; Frankfurt et al., 1990; Gibbs, 1996; Woolley et al., 1990). These effects are transient and may not necessarily be considered “permanent features,” but nevertheless constitute a part of what makes the female brain distinct from the male brain. Females clearly have an inherent “permanently cyclic” and dynamic neural landscape that modifies along with the reproductive cycle (Fitch and Denenberg, 1998). Moreover, these “permanently cyclic” features have potentially important relevance to cognitive aging since gonadal hormones can impact memory, and gonadal hormone levels change with age (Bimonte-Nelson et al., 2010; Conrad and Bimonte-Nelson, 2010). For the remainder of this review, we focus on the activational effects of female steroid hormones on cognitive function and brain health during aging in females, defining these effects as transient and depending on the presence of hormone.

4. Menopause etiology

Studies have shown that ovarian hormone loss negatively impacts cognition in women, and that these effects correspond to the associated estrogen deficiency (Farrag et al., 2002; Phillips and Sherwin, 1992; Sherwin, 1988). Others have shown modest, but statistically significant, declines in cognitive performance in women after surgical menopause, but express that the effects were small and not likely to be of clinical significance (Kritz-Silverstein and Barrett-Connor, 2002). In numerous studies, cognitive decline has been seen in women after surgical menopause (Farrag et al., 2002; Phillips and Sherwin, 1992; Sherwin, 1988). For example, surgical menopause negatively impacted performance on tests of global cognitive function by three months after surgical ovarian hormone loss, an effect that persisted six months post-surgery (Farrag et al., 2002). Further, surgically menopausal women demonstrated lower memory scores relative to naturally menopausal women, and age of oophorectomy (surgical ovary removal) and greater years since surgery correlated with

poorer performance (Nappi et al., 1999). A recent longitudinal study evaluating, 1,903 women from the years 2000–2006 found decreased cognitive processing speed in women during late perimenopause, effects not attributed to depression, anxiety, sleep irregularities, or vasomotor symptoms (Greendale et al., 2010). Memory complaints were also associated with poorer memory encoding in women transitioning into menopause, and this was predicted by estrogen levels (Weber and Mapstone, 2009). Moreover, a recent elegantly performed study evaluated cognitive change across time in postmenopausal women, controlling for age and education (Thilers et al., 2010). Results showed a decline in verbal fluency with postmenopause, as well as declines in visuospatial ability and episodic memory measures; the latter effects were greater in women with a body mass index over 25, as compared to those with a lower body mass index considered within the normal range (18.5–25; Thilers et al., 2010). Together, results in women support the hypothesis that decreases in endogenous estrogen levels concordant with postmenopause have a negative influence on cognitive abilities, although this effect is modest in some studies, and may depend on several factors including women's stage of the menopause transition, time since menopause induction if surgical, and body mass index. Age may be another factor, as increased risk of cognitive impairments was found in surgically menopausal women, and risk increased with younger age at surgery (Rocca et al., 2007).

Preclinical evaluations in rats also provide evidence that ovarian hormone loss impacts cognition. Because these pre-clinical studies allow methodical manipulation of factors that could impact outcome, the results from these studies can systematically demonstrate that hormone effects depend on many factors, including age (Bimonte-Nelson et al., 2003, 2004b; Bimonte et al., 2003; Markowska and Savonenko, 2002; Savonenko and Markowska, 2003; Talboom et al., 2008). Indeed, cognitive decrements on spatial and non-spatial tasks have been observed in young adult rats in response to surgical menopause (Ovx) (Bimonte and Denenberg, 1999; Daniel et al., 1999; El-Bakri et al., 2004; Feng et al., 2004; Gibbs and Johnson, 2008; Singh et al., 1994; Talboom et al., 2008; Wallace et al., 2006). In contrast, OvX in aged rats may be beneficial to cognition. Our laboratory showed that OvX impaired working memory on the water radial arm maze in young animals (Bimonte and Denenberg, 1999), yet, initially to our surprise, years later we found OvX-induced cognitive enhancements on the same task with aged OvX animals performing better than age-matched ovary-intact sham animals (Bimonte-Nelson et al., 2003). Moreover, we have replicated this finding multiple times, and our research indicates that the OvX-induced enhancements are likely due to removal of elevated progesterone levels seen with estropause in the rat (Bimonte-Nelson et al., 2003, 2004b; Braden et al., 2010). At this point then, we know that OvX in young animals is detrimental, and OvX in aged animals is beneficial, for water radial arm maze working memory performance. The next question is, “when during aging does OvX transition from detrimental to beneficial for the rat?”. The cognitive effects of OvX during middle age are less clear, as only a few studies have evaluated OvX effects on maze learning and memory in middle-aged rats (Acosta et al., 2009a;

Bimonte-Nelson et al., 2006; Markowska and Savonenko, 2002; Savonenko and Markowska, 2003; Talboom et al., 2008). In middle-aged females 12–16 months-old, Ovx did not impact spatial reference memory (Acosta et al., 2009a; Bimonte-Nelson et al., 2006; Markowska and Savonenko, 2002; Talboom et al., 2008) or spatial working memory (Acosta et al., 2009a; Markowska and Savonenko, 2002; Savonenko and Markowska, 2003), as well as tasks on which either a spatial or non-spatial strategy can be used for successful performance (Markowska and Savonenko, 2002; Savonenko and Markowska, 2003). Deficits in spatial working memory were, however, detected in 17 month old Ovx rats following high-demand time delayed memory retention tests, as compared to ovary-intact controls (Markowska and Savonenko, 2002). Thus, Ovx-related memory changes during middle-age may become evident when working memory demands are more challenging. In this regard, we previously demonstrated that the cognitive effects of Ovx in both young and old rats were more pronounced as working memory load increased (Bimonte-Nelson et al., 2003, 2004b; Bimonte and Denenberg, 1999; Braden et al., 2010). Hence, increasing the working memory demand, either by extending time delays to challenge retention, or by increasing the number of items to remember, facilitates a broader scope of evaluations to realize Ovx-induced memory changes across age. A study methodically testing the effects of Ovx at different ages ranging from young adulthood to old age is necessary to determine the age at which Ovx transitions from detrimental to beneficial. Determining brain changes associated with this transition are not only important for clarifying mechanisms of menopause-related learning and memory alterations, but could also yield valuable information on underlying mechanisms of cognitive aging and potential mechanisms of HT-induced enhancements.

Preclinical research in rats has yielded much insight regarding the cognitive impact of Ovx effects across the lifespan. Of note, the majority of women undergo menopause as a transitional loss of ovarian hormones due to age-related alterations of the hypothalamus, pituitary, and ovary, ultimately resulting in ovarian follicular depletion, rather than an abrupt loss of ovarian hormones via oophorectomy (Quirion et al., 1995). In addition, there are distinct differences in the mechanism and hormone profile of senescent female rats and women that preclude the use of the ovary-intact aging female rat as the sole and optimal model for menopause. In women, menopause occurs at about the fifth decade of life and is characterized by loss of ovarian-derived circulating hormones, including estrogen and progesterone (Quirion et al., 1995). For both women and female rats, neural changes in the hypothalamus are hypothesized to initiate the transition into reproductive decline, leading to reproductive senescence (Downs and Wise, 2009). However, the ultimate hormone profile of ovary-intact reproductively senescent female rats and woman differ, limiting the use of the normally aging female rat as an optimal model of human menopause. Nonetheless, the rodent model provides insights into mechanisms of menopause since there are some commonalities in reproductive physiology (Downs and Wise, 2009).

In women, as aging ensues, estrogen and progesterone decline due to decreased ovarian follicular reserves (Quirion

et al., 1995). Thus, menopause is the cessation of ovarian cyclicity, ultimately caused by ovarian follicular depletion. In contrast, the aging rat undergoes estropause, a persistent estrus state due to chronic anovulation rendering intermediate estrogen levels, or a pseudopregnant/persistent diestrus state characterized by high progesterone levels due to increased ovulation and corpora lutea (Meites and Lu, 1994). These changes in ovarian-derived hormone release in the rat are primarily due to hypothalamic/pituitary axis alterations (Downs and Wise, 2009; Meites and Lu, 1994). Thus, the primary mechanism that ultimately results in reproductive senescence and circulating hormone alterations in the woman is ovarian follicular depletion, while in the rat it is the hypothalamic-pituitary axis.

Transitional hormone loss can be induced in rodents via administration of the industrial chemical 4-vinylcyclohexene diepoxide (VCD) (Mayer et al., 2002, 2004; Springer et al., 1996). VCD produces follicular depletion by selectively destroying primordial and primary follicles via acceleration of the natural process of atresia, resulting in hormone profiles in rodents that are more similar to naturally menopausal women as compared to Ovx (Mayer et al., 2002, 2004; Springer et al., 1996; Timaras et al., 1995). We recently showed that VCD-induced transitional menopause impaired learning of a spatial recent memory task (Acosta et al., 2009a). We also demonstrated that rats undergoing transitional menopause before Ovx was better for spatial memory than an abrupt loss of hormones via Ovx without the prior transition (Acosta et al., 2009a). Nappi et al. (1999) showed that in women poorer cognitive scores corresponded with a longer duration of hormone deprivation from oophorectomy. It is of note that in that study, surgically menopausal women were younger at menopause than naturally menopausal women. Therefore, it is plausible that those surgically menopausal women did not undergo an extended period of transitional menopause before surgical menopause, and thus did not have benefits due to a transitional hormone decline prior to oophorectomy. In fact, Rocca et al. (2007) found that women that had undergone oophorectomy prior to menopause onset showed an elevated risk of cognitive impairment as compared to age-matched women without oophorectomy. In addition, risk of cognitive impairment increased as age at oophorectomy decreased, which presumably limited the duration of transitional menopause. Further evaluations of women receiving oophorectomy before, versus after, transitional menopause will better discern whether history of transitional menopause before surgical ovarian removal affects subsequent cognitive change. It is possible that an as yet undetermined duration of transitional menopause before oophorectomy is optimal for cognitive outcome, a tenet supported by the animal literature; indeed, this would obviate the abrupt ovarian hormone loss associated with oophorectomy.

5. Estrogens

Estrogens are a class of hormones including 17 β -estradiol, estrone, and estriol. 17 β -estradiol is the most potent naturally-circulating estrogen, followed by estrone and estriol, in order of receptor affinity (Kuhl, 2005; Sitruk-Ware,

2002). Since the first controlled clinical evaluation showing that 17 β -estradiol injections enhanced memory in 75 year-old women (Caldwell and Watson, 1952), numerous studies have demonstrated cognitive decline after ovarian hormone loss, and enhancement after treatment with various types of estrogen-containing preparations, in menopausal women (for a review see Sherwin, 2006). Conjugated equine estrogens (CEE; tradename Premarin[®]), is the most commonly prescribed HT given to women (Hersh et al., 2004). CEE contains the sulfates of at least ten estrogens, is over 50% estrone sulfate, 20–25% equilin sulfate, and has only trace amounts of 17 β -estradiol. After CEE is metabolized, the resulting primary circulating hormones are estrone and, after estrone's conversion, 17 β -estradiol, as well as equilin (Bhavnani, 2003; Sitruk-Ware, 2002). It is hypothesized that these three metabolites are primarily responsible for the estrogenic effects of CEE (Sitruk-Ware, 2002), although there are other estrogens and related metabolites that could initiate effects on their own; these hormones include, but are not limited to equilin, $\Delta^{8,9}$ -dehydroestrone, dihydroequilin-17 β , and equilenin (Kuhl, 2005).

The cognitive effects of CEE are mixed. CEE-containing HT improves memory in studies of women utilizing self-report (Campbell and Whitehead, 1977), case studies (Ohkura et al., 1995) and randomized psychometric evaluations (Kantor et al., 1973). Yet, findings evaluating global cognitive function in the large placebo-controlled WHI Memory Study (WHIMS) demonstrated an increase in probable dementia risk and no effect on mild cognitive impairment in women 65 years or older taking the combination therapy CEE+the progestin, medroxyprogesterone acetate (MPA, Shumaker et al., 2003). CEE alone showed a non-significant increase in incidence of probable dementia and mild cognitive impairment (Espeland et al., 2004; Shumaker et al., 2004). The WHI Study of Cognitive Aging (WHISCA), an ancillary study to the WHI testing more specific cognitive functions, in women 65 and over free of probable dementia, reported that CEE+MPA therapy had a negative effect on verbal memory and a trend for positive effects on figural memory (Resnick et al., 2006). Most recently, the WHIMS-MRI study found that CEE use with or without MPA was associated with small but measurable atrophy in the frontal cortex and hippocampus (Resnick et al., 2009), brain regions important for cognition. Thus, there is currently little consensus in clinical studies regarding the cognitive impact of estrogen-containing HT. New investigations clarifying the complex effects of ovarian hormone loss and HTs given to women during aging are warranted.

Crucial to advancement of the field is identifying the various administration parameters and components of HTs that impact outcomes on cognition. Detailed hypothesis-driven and methodical assessments using basic science and system approaches are optimal for converging the many findings that seem contradictory. With emerging data and results from these types of studies, it is becoming clear that the cognitive effects of HT may not be contradictory at all. Findings may, in fact, be dependent on numerous variables not yet taken into account. One way to further our understanding of the impact of gonadal hormone loss and therapeutic interventions on cognition is by using animal models. Rodent models have been invaluable in providing insight into the cognitive effects of HTs administered after ovarian

hormone loss, while enabling experimental control not possible in human research. Most preclinical studies have utilized 17 β -estradiol to test cognitive effects of HT in Ovx animals. For example, numerous studies have reported beneficial effects of 17 β -estradiol on spatial learning and memory in young (Bimonte and Denenberg, 1999; Daniel et al., 1997, 1999; Dohanich et al., 1994; Galea et al., 2001; Holmes et al., 2002; Luine et al., 1998, 2003; Marriott and Korol, 2003; McLaughlin et al., 2008; Packard and Teather, 1997b; Sandstrom and Williams, 2001) and in middle-aged or older female rats (Bimonte-Nelson et al., 2006; Foster et al., 2003; Gibbs, 2000b; Markham et al., 2002; Markowska and Savonenko, 2002; Savonenko and Markowska, 2003; Talboom et al., 2008; Ziegler and Gallagher, 2005). Effects of 17 β -estradiol treatment in young and middle-aged rodents are also observed on the non-spatial visual object recognition task whereby animals are tested on whether they “recognize” a novel object (operationally defined by increased exploration of the novel object; Fernandez et al., 2008; Lewis et al., 2008; Luine et al., 2003).

Recently, our laboratory examined the effects of both tonic and cyclic CEE administration. In these rodent studies, the doses of CEE administered were relevant to what women take as HT, with the clinically-used dose only adjusted for body weight. We demonstrated that CEE enhanced spatial working memory and delayed memory retention, and protected against cholinergic challenge on spatial tasks, in Ovx middle-aged rats (Acosta et al., 2009b; Engler-Chiurazzi et al., 2011). Further, a single high dose CEE injection enhanced non-spatial working memory object recognition (Walf and Frye, 2008). However, low CEE doses have been shown to impair spatial working and reference memory performance (Barha and Galea, 2012; Engler-Chiurazzi et al., 2011), an effect we hypothesized to be due to higher circulating levels of estrone relative to 17 β -estradiol, resulting after specific doses of CEE administration (Engler-Chiurazzi et al., 2011). Indeed, animals receiving low dose CEE showed increased serum estrone levels, while no increases were found in 17 β -estradiol levels, relative to control animals (Engler-Chiurazzi et al., 2011; but see, Barha and Galea, 2012). Moreover, increases in circulating estrone levels were associated with greater working memory errors in rats (Barha and Galea, 2012) and lower cognitive scores in women (Yaffe et al., 1998).

Therefore, our next goal was to methodically evaluate the impact of estrone on learning and memory in middle-aged rats. In contrast to the beneficial effects of CEE in Ovx rats, estrone treatment impaired spatial working memory and memory retention, and did not alter number of choline acetyltransferase (ChAT, the synthesizing enzyme of acetylcholine)-positive basal forebrain neurons, as does 17 β -estradiol (Engler-Chiurazzi et al., 2011; 2012). Hence, evidence thus far indicates that estrone, the primary active metabolite after CEE administration in rats and women, is detrimental for cognition. To extend evaluations to other CEE components, we tested the cognitive effects of $\Delta^{8,9}$ -dehydroestrone and equilin, two CEE components identified to be neuroprotective in vitro (Zhao and Brinton, 2006). We found that chronic $\Delta^{8,9}$ -dehydroestrone treatment enhanced memory, whereas equilin had no effect, in Ovx rats (Talboom et al., 2010). Thus, other CEE components may have functional benefits on cognition, providing new treatment opportunities.

Responsiveness to estrogens may depend on many variables other than type of estrogen, including age. Young and middle-aged Ovx rats showed beneficial effects of 17 β -estradiol treatment on the spatial reference memory Morris water maze task, and higher circulating 17 β -estradiol levels correlated with better performance (Talboom et al., 2008). In contrast, aged Ovx rats were not responsive to the same 17 β -estradiol regimen that enhanced spatial reference memory in young and middle-aged Ovx rats (Talboom et al., 2008), corresponding to age-related interactions with 17 β -estradiol treatment for spatial memory shown by others (Foster et al., 2003). However, some studies have shown that aged female rodents can exhibit cognitive enhancements after 17 β -estradiol treatment. For example, 17 β -estradiol injections enhanced spatial reference memory in 27–28 month old ovary-intact mice (Frick et al., 2002). The difference in results may relate to the type of 17 β -estradiol administration as a cyclic versus tonic regimen. In this regard, for cognition, one study showed that cyclic 17 β -estradiol treatment enhanced responsiveness to tonic 17 β -estradiol treatment in older Ovx rats (Markowska and Savonenko, 2002).

In addition to age, estrogenic effects on cognition may be influenced by many other factors including, but not limited to, timing of hormone administration relative to hormone loss, dose, mode of treatment, and whether progestogens are administered concomitantly. Some of the translational questions driving much of the newer preclinical research studying estrogens' impact on brain health and cognition during aging have been directly spawned from the WHIMS findings. Women participating in the WHIMS were between 65–79 years old, and had presumably experienced ovarian hormone deprivation for a substantial amount of time prior to receiving CEE treatment (Shumaker et al., 1998). These findings beg the question of whether there is a window of opportunity for which HT can be effective. Recent preclinical studies found evidence of this. 17 β -estradiol given immediately after Ovx enhanced spatial memory performance in middle-aged rats, but had no benefit when given 5 months after Ovx (Daniel et al., 2006). Additionally, 17 β -estradiol treatment given immediately after Ovx increased cholineacetyltransferase (ChAT) levels in the hippocampus, an increase not seen when initiated 5 months after Ovx; the opposite pattern was seen in prefrontal cortex, wherein 17 β -estradiol treatment given 5 months after Ovx, but not immediately after Ovx, increased prefrontal cortex ChAT levels (Bohacek et al., 2008). Further, 17 β -estradiol given immediately or 3 months after Ovx, but not 10 months after Ovx, enhanced delayed-match-to-position performance (Gibbs, 2000b). There may also be a critical window for the well-established findings that 17 β -estradiol regulates dendritic spines in the hippocampus (Woolley, 2000). We found that a 10 week delay after Ovx attenuated the effectiveness of 17 β -estradiol-induced increases in CA1 apical dendritic spine density, as compared to treatment given immediately (McLaughlin et al., 2008). Further, increased cell proliferation was observed in the dentate gyrus when 17 β -estradiol was administered 1 week, but not 4 weeks, after Ovx (Tanapat et al., 2005). Thus, clinical and preclinical findings concur that the beneficial effects of estrogens may be dependent on early initiation relative to ovarian hormone loss (Khoo et al., 2010; Sherwin, 2005). However, the specific temporal parameters of

these effects have not been discerned, and it remains unclear whether these findings can be extended to estrogens other than 17 β -estradiol.

Important to the discussion of parameters contributing to the complexity involved in the cognitive impact of HT, is the consideration of menopause history (surgical or transitional). Although our laboratory recently found that CEE was beneficial for cognition (Acosta et al., 2009b, 2010; Engler-Chiurazzi et al., 2011), we observed that these benefits were limited to rats that had undergone surgical menopause (Acosta et al., 2010). In surgically menopausal (Ovx) rats, CEE enhanced reference and working memory (Acosta et al., 2010). In contrast however, VCD-induced transitionally menopausal rats showed the opposite effect after CEE administration, with a CEE-induced increase in errors on these measures (Acosta et al., 2010). Further, CEE-treated Ovx rats showed better memory retention across an 8-hr delay relative to vehicle-treated Ovx rats, while CEE exerted no retention benefit in VCD transitionally menopausal rats (Acosta et al., 2010). Thus, CEE was beneficial after surgical menopause, but detrimental after transitional menopause (Acosta et al., 2010). Accordingly, human studies evaluating surgically menopausal women after hormone treatment show cognitive benefits of HT (Phillips and Sherwin, 1992; Sherwin, 1988), consistent with our CEE findings in Ovx rats (Acosta et al., 2009b, 2010; Engler-Chiurazzi et al., 2011). Reports of positive effects of HT in studies including only oophorectomized women, and the current findings of differential cognitive effects of CEE depending on menopause history in the rodent model, collectively suggest that menopause history is a plausible factor that contributes to cognitive efficacy of HT.

6. Progestogens

Progestogens include steroids with a pregnane skeleton, including naturally-occurring progesterone as well as progestins (synthetic progesterones). Inherent to any discussion on the impact of HT on cognition and the complexities involved in outcome, is that of combination therapy, which includes estrogen plus a progestogen concomitantly. Investigating combination therapy is crucial since women with a uterus taking estrogens must include a progestogen in their regimen to offset the increased risk of endometrial hyperplasia associated with unopposed estrogen treatment (Smith et al., 1975). Progestins may have a negative impact on cognition in women. For example, findings demonstrated that menopausal women taking CEE alone did not significantly differ from those taking placebo for dementia diagnoses in the WHIMS (Shumaker et al., 2004); in contrast, twice as many women receiving CEE plus the synthetic progestin MPA were diagnosed with dementia as compared to the placebo group in the WHIMS (Shumaker et al., 2003).

Rodent models have been instrumental in deciphering some of the complexities associated with combination therapy. In a rodent study of combination treatment, we showed that natural progesterone abolished 17 β -estradiol-induced benefits on the spatial reference memory Morris water maze in middle-aged rats (Bimonte-Nelson et al., 2006). Additionally, while natural progesterone or 17 β -estradiol

alone did not influence performance on the Morris water maze (Chesler and Juraska, 2000), progesterone plus 17 β -estradiol injections did impair performance (Chesler and Juraska, 2000; Lowry et al., 2010). These effects were not seen on the non-spatial version of the Morris water maze, suggesting combination treatment has specific effects within the spatial domain (Chesler and Juraska, 2000). Although more work clearly needs to be done in this area, it is noteworthy that progesterone does not always impair memory in combination with an estrogen, as long-term progesterone treatment enhanced 17 β -estradiol's effects on the working memory delayed-match-to-position spatial t-maze (Gibbs, 2000b, but see Chisholm and Juraska, 2012). It is likely that further research will show that type of maze, and maze acquisition/learning versus memory, impacts direction-specific outcomes of hormone treatment.

In both clinical and preclinical studies, progesterone administration has been associated with cognitive detriment. In pregnant women, there is the reported "maternal amnesia" phenomenon, hypothesized to result from high circulating progesterone levels during late pregnancy (Brett and Baxendale, 2001). Progesterone-induced memory detriments are also seen in healthy women; indeed, healthy women given a high oral progesterone dose showed cognitive impairment (Freeman et al., 1992). High circulating progesterone levels are evident following estropause in the rat (Lu et al., 1979). Many aged female rats enter a pseudopregnant estropause state, whereby progesterone values become significantly elevated, but 17 β -estradiol levels remain relatively unchanged (Huang et al., 1978; Wise and Ratner, 1980). This pseudopregnant state has been associated with impaired spatial memory (Warren and Juraska, 2000). Similarly, on the spatial reference memory Morris water maze, young cycling rats performed best during the estrus phase, when estrogen and progesterone levels are at their lowest, and worst during the proestrus phase, when estrogen and progesterone levels are at their highest (Warren and Juraska, 1997, but see Berry et al., 1997; Stackman et al., 1997). Further, in contrast to the detrimental effects of Ovx in young animals, in aged female rats Ovx improves cognition (Bimonte-Nelson et al., 2003, 2004b), an effect likely due to the removal of elevated progesterone levels seen with estropause. We have also shown that progesterone administration impairs spatial working and reference memory, and reverses the beneficial effects of Ovx seen in aged rats (Bimonte-Nelson et al., 2004b; Braden et al., 2010).

Since the synthetic MPA is the progestin component in the commonly prescribed HT, Prempro[®] (CEE+MPA), it was a goal of our laboratory to examine the impact of MPA on a cognitive battery in a controlled rodent experiment. We found that MPA impaired memory retention after a delay on the water radial arm maze, and exacerbated overnight forgetting on the spatial reference memory Morris water maze task (Braden et al., 2010). MPA treatment also impaired spatial working memory, and detriments were particularly pronounced as the working memory load increased (Braden et al., 2010). Of note, MPA is also the sole hormone in the contraceptive Depo Provera[®]. While no clinical study has directly evaluated the impact of MPA on cognitive health in younger women using this contraceptive, one case study reported amnesic effects

corresponding with Depo Provera[®] use in young women (Gabriel and Fahim, 2005). To further investigate our findings of MPA-induced cognitive impairments during aging, we conducted a study evaluating the long-term effects of MPA. Results showed that MPA administration in either young adulthood, middle-age, or at both times, impaired working memory when measured at the middle-aged time point (Braden et al., 2011). The deleterious effects of MPA were greater when animals received treatment during both young adulthood and middle-age, as impairments were observed on two orthogonal measures of working memory and, in particular, on trials with higher working memory demand (Braden et al., 2011). Further, combination MPA plus 17 β -estradiol treatment was detrimental on the spatial reference memory Morris water maze task relative to other hormone-treated groups, including progesterone plus 17 β -estradiol treatment (Chisholm and Juraska, 2012). The detrimental effects of MPA in combination with 17 β -estradiol may be task and cue-use dependent, as chronic administration of MPA plus 17 β -estradiol was beneficial on an alternation t-maze task, a task which can be solved using either a spatial or a non-spatial strategy (Chisholm and Juraska, 2012).

Collectively, evidence spanning clinical and basic science realms indicates progestogens negatively impact neuronal health, which could result in detrimental effects on brain functions such as learning and memory. Progesterone abolishes the beneficial effects of 17 β -estradiol (Bimonte-Nelson et al., 2006; Harburger et al., 2007, but see Gibbs, 2000b) and attenuates 17 β -estradiol's neurotrophic effects in vivo (Bimonte-Nelson et al., 2004a) and in vitro (Aguirre and Baudry, 2009). Progesterone has been shown to have neuroprotective properties, while MPA does not (Nilsen and Brinton, 2002). Relative to progesterone, MPA results in greater attenuation of 17 β -estradiol-induced neurotrophic actions (Nilsen and Brinton, 2002). Thus, while a progestin is necessary as part of HT in women that have a uterus (Smith et al., 1975; Ziel and Finkle, 1975), accumulating evidence indicates that the addition of a progestin does not result in a positive impact on brain health and function during aging. Progestins are an important and necessary component of HT for many women and should not be undervalued. A systems and personalized approach, valuing and accounting for multiple aspects of women's health, is key to optimizing HT.

7. Androgens

Androgens are typically thought of as a "male" hormone; a masculinizing hormone which initiates permanent organizational effects on the male brain during a specific critical period in early development, and an activating hormone for male sex behaviors in adulthood. Why study androgens in females as a potential modulator of learning and memory? From our perspective, studying the impact of androgens on cognition in the female rodent model is important for several reasons. First, androgens bind to and activate the androgen receptor, which are expressed in the female brain. In particular, brain areas found to be important for cognition, such as the hippocampus and cerebral cortex, have been shown to express high concentrations of androgen receptors in female

rodents (Simerly et al., 1990). Second, activation of these androgen receptors could ultimately impact cognition, as it results in changes in neuronal function via altering gene transcription (McPhaul and Young, 2001). Third, levels of androgen receptors in cognitive brain regions have been found to be modulated by Ovx and androgen administration, showing that androgen receptor levels are dependent upon circulating levels of androgens (Lu et al., 1998). It is therefore clear that androgens could play an important role in normal brain functioning in female rodents. How androgens impact cognition in female rodents is still being deciphered, as research in this area is emerging. This portion of the review will focus on the androgens that have been most studied, for cognition which are testosterone, dihydrotestosterone (DHT), and androstenedione.

Relations between endogenous testosterone levels and cognition have been noted in younger and older individuals. In general, the strongest associations have been seen in the older population in retrospective and randomized treatment studies. For example, testosterone was related to cognitive performance in young men and women, and spatial ability was related to seasonal changes in accordance with related alterations in testosterone levels (Kimura and Hampson, 1994; Neave et al., 1999; Silverman et al., 1999). Some evidence suggests an inverted function for testosterone levels and spatial ability, with moderate levels optimal. An excellent example of this function, which also exemplifies the importance of a broad perspective when analyzing the cognitive effects of hormones, is shown via the insight of Dr. Doreen Kimura. For example, in one study, when males and females were both included in analyses, the perspective of an inverted U-shaped function was realized; this was not clearly evident when the sexes were analyzed separately. Specifically, higher relative levels of salivary testosterone were associated with better spatial ability performance in women, and lower relative levels of salivary testosterone were related to better spatial ability performance in men (Gouchie and Kimura, 1991).

Testosterone's mnemonic effects could be due to conversion to DHT, or to conversion into estrogen indeed, testosterone can be converted to either DHT (which binds to androgen receptors) via 5 α reductase, or to estrogen via the aromatase enzyme (Becker, 1995). Several studies have been conducted assessing the impact of various types of androgens on cognition in the female rodent model. Benice and Raber, 2009 assessed the impact of androgen supplementation on cognition in the aged (20 to 22 month old) female mouse model by administering either testosterone, testosterone's metabolite DHT, or vehicle, followed by testing on the Morris water maze, novel object recognition, and passive avoidance. Testosterone, but not DHT, improved performance on the Morris water maze, as compared to vehicle, suggesting that testosterone's conversion to estrogens relates to the impact of testosterone treatment for spatial reference memory (Benice and Raber, 2009). Enhancements may be specific to spatial navigation, since testosterone did not impact any other measure (Benice and Raber, 2009). In addition, DHT, but not testosterone, impacted passive avoidance scores, and neither DHT nor testosterone affected novel object recognition scores (Benice and Raber, 2009). Androgen-

induced enhancements may be of a broader nature in younger animals, as administration of either DHT or testosterone enhanced performance on the Y-maze, passive avoidance, and novel object recognition in 3 month old Ovx rats (Frye and Lacey, 2001). In this study, it is noteworthy that hormones were given post-training, thereby obviating issues of motivational or other non-cognitive factors that could impact interpretation of effects.

We have recently found evidence that the androgen androstenedione negatively impacts cognition in the female rat. This discovery was initially made via a correlational analysis between endogenous androstenedione levels and maze error scores, and then confirmed with experimental manipulation whereby androstenedione was exogenously administered (Acosta et al., 2009a, 2010; Camp et al., 2012). Initially, we demonstrated that transitionally menopausal (VCD treated) middle-aged female rats exhibited superior cognitive scores across multiple domains, as compared to rats that had undergone surgical menopause. However, this effect was only apparent when the post-VCD follicle-deplete ovary was removed via Ovx. One of the more surprising findings from this study was that higher serum levels of androstenedione, which is released from the follicle-deplete menopausal ovary, correlated with poorer memory scores in VCD rats (Acosta et al., 2009a). In a follow-up study evaluating cognitive effects of CEE HT in transitionally and surgically menopausal rats, we again found a correlation between higher androstenedione levels and impaired performance in transitionally menopausal rats (Acosta et al., 2010). This correlation was evident for reference memory and two orthogonal working memory measures (Acosta et al., 2010). Importantly, these correlations were shown in ovary intact animals that had VCD treatment, which renders an androgen-rich environment from the postmenopausal ovary (Acosta et al., 2009a, 2010). If androstenedione is in fact related to poorer memory, impairments should be evident after androstenedione administration to a "blank" ovarian hormone template. We tested this hypothesis in a study in which middle-aged (14 month old) Ovx rats were treated with one of two doses of androstenedione, or vehicle, and tested on a cognitive battery. Androstenedione administration that resulted in blood levels at the higher end of the physiological range in the female rat impaired spatial reference memory on the Morris water maze, impaired performance on the water radial arm maze when the working memory load was at its greatest, and impaired memory retention on a win-stay delay match to sample task, as compared to vehicle treatment (Camp et al., 2012). Thus, a correlation in the rat model showing that higher endogenous androstenedione levels were related to poorer memory performance led to methodical investigation and manipulation in the rat model; results showed that this androgen, released from the follicle-deplete ovary in both women and rats, markedly impairs memory.

8. Gonadotropins

Although it is well established that the gonadotropins (peptide hormones released from the anterior pituitary) follicle stimulating hormone (FSH) and luteinizing hormone (LH) are

involved in regulating reproductive functions via negative and positive feedback loops, increasing evidence is indicating that gonadotropins, directly or indirectly, impact cognitive function as well, including within the spatial domain. Although the links between FSH and cognition do not appear to be realized (e.g., Acosta et al., 2009a; Luetters et al., 2007), there is strong evidence that LH is related to cognition, with the greatest support coming from the neurodegenerative disease literature (Webber et al., 2007). Supporting plausibility of LH effects on the brain and spatial cognition, it is of note that LH can cross the blood-brain-barrier (Lukacs et al., 1995). In addition, the highest density of LH receptors in the brain are found in the hippocampus (Lei et al., 1993; Zhang et al., 1999), a brain region intimately involved in spatial learning and memory, and affected by aging and AD.

We recently evaluated VCD-induced follicular depletion and Ovx effects on cognition in the middle-aged rat, and found a clear inverted U-shaped function for serum LH and number of spatial memory errors, with the highest and lowest LH levels associated with the best performance (Acosta et al., 2009a). A comparable effect was not seen with FSH (Acosta et al., 2009a). This relationship between LH and performance became apparent in scatterplots including all treatment groups, so that the range of values across groups could be noted (conceptually similar to Kimura's procedure described above; Gouchie and Kimura, 1991). This range of values was broad, because, as expected, Ovx increased LH levels due to a lack of ovarian hormone negative feedback after ovarian hormone loss, while sham control animals showed LH values in a lower relative range. When LH levels ranged from approximately 0-to-2 ng/ml, higher LH levels correlated with worse maze performance thereby revealing a positive relationship with errors. However, when LH levels ranged from approximately 2-to-10 ng/ml, higher LH levels correlated with better maze performance thereby revealing a negative relationship with errors (Acosta et al., 2009a). We noted a striking inverted U-shaped function when the groups were combined into the same scatterplot. This pattern was seen for multiple measures, including both spatial working memory and spatial reference memory. While there are limitations in this study in interpreting this relationship because LH levels were confounded by group membership, this quadratic relationship is nonetheless remarkable. Understanding this relationship between LH and memory can have clinical significance, especially given increasing evidence that LH levels are linked to pathologies associated with neurodegenerative disorders, as well as cognition (Webber et al., 2007). There are other studies reporting that higher LH levels are related to better cognitive performance, similar to the effects seen in our study in the Ovx animals. For example, tonic LH-releasing hormone treatment to elevate LH concentrations to Ovx levels, enhanced performance on visual-discrimination in young rats (Nauton et al., 1992), and enhanced non-spatial working memory in aged rats (Alliot et al., 1993). Relations between higher LH and better memory in these studies are likely related to LH levels being increased to that of Ovx animals. In contrast, corresponding with the Acosta et al. (2009a) findings in ovary-intact animals that higher LH levels correlated with poorer cognitive performance, in aged ovary-intact female mice, experimentally-induced LH attenuation decreased

amyloid- β concentrations and enhanced cognition, while LH increases promoted biochemical brain changes consistent with AD; however, none of these studies correlated circulating LH levels with memory scores in individual subjects (Bowen et al., 2004; Casadesus et al., 2006, 2007). Other supporting evidence shows that men and women with AD had higher circulating LH levels than controls (Bowen et al., 2004; Short et al., 2001).

The growing literature evaluating the relationship between LH levels and cognitive performance suggests that it may subserve an inverted U-shaped function, with lower and higher levels resulting in optimal learning and memory, and intermediate levels resulting in poorest learning and memory. This is an important area that will require further study, with results possibly revealing important mediators of cognitive function. Effects could explain, in part, how hormone modulation impacts learning and memory.

9. Female steroids and cognition: Landmark and most recent putative mechanisms of ovarian hormone action

9.1. Cholinergic and γ -aminobutyric acid (GABA)ergic systems

Abundant evidence suggests that the cholinergic and GABAergic systems are intimately related to the effects of female steroids on cognition. Pharmacological experiments using both peripheral and intracranial infusions show that the cholinergic system may mediate estrogen-induced effects. Much of the landmark work evaluating relations between estrogens and the cholinergic system has been done via the creative and methodical approach of combining hormones and pharmaceutical agents in the laboratory of visionary Dr. Robert Gibbs. In middle-aged Ovx rats, galanthamine, a cholinesterase inhibitor, combined with 17 β -estradiol enhanced acquisition of a delayed matching to position (DMP) T-maze task relative to vehicle treatment, while the effects of 17 β -estradiol or galanthamine alone did not differ from vehicle (Gibbs et al., 2011a). Donepezil, another cholinesterase inhibitor, combined with 17 β -estradiol enhanced acquisition of the DMP task in animals with cholinergic lesions (<50% loss of cholinergic neurons), whereas 17 β -estradiol and donepezil alone were ineffective (Gibbs et al., 2011b). 17 β -estradiol has also been shown to alter cholinergic markers in the brain. In young adult Ovx rats given 17 β -estradiol, maze acquisition correlated with increased ChAT activity in two targets of basal forebrain cholinergic innervation, the hippocampus and frontal cortex (Gibbs, 2002), and 17 β -estradiol increased high affinity choline uptake in these regions (O'Malley et al., 1987; Singh et al., 1994). 17 β -estradiol increased ChAT in the horizontal limb (Luine and McEwen, 1983; Luine, 1985; Singer et al., 1998) and in projection sites to hippocampus and cortex (Feng et al., 2004; Luine, 1985; Singh et al., 1994), and restored basal forebrain ChAT mRNA expression to levels of ovary-intact animals (Gibbs et al., 1994; McMillan et al., 1996). Lesioning the basal forebrain prevented 17 β -estradiol-enhanced learning, indicating the basal forebrain is a key area through which 17 β -estradiol cognitive enhancements occur (Gibbs, 2002, 2007). Other

estrogens may also alter cholinergic markers, as we recently showed that CEE enhanced the number of ChAT immunoreactive neurons in the vertical diagonal band of the basal forebrain. Estrogens may also alter cholinergic neurochemistry, as 17 β -estradiol potentiated acetylcholine (ACh) release in the hippocampus during maze learning; this is especially noteworthy since the hippocampus is a primary projection site of the basal forebrain (Marriott and Korol, 2003).

Interestingly, increased release of ACh in the hippocampus may lead to muscarinic receptor M2 activation, which in turn, can suppresses the release of GABA (Birzniece et al., 2006; Daniel and Dohanich, 2001; Daniel et al., 2005). Hence, estrogen-mediated increases in ACh signaling through muscarinic activation may release hippocampal inhibition, and in turn allow for alterations in synaptic plasticity that may ultimately lead to enhanced cognition (Rudick and Woolley, 2001). However, ACh can also stimulate nicotinic receptors and activate GABA interneurons in CA1 (Alkondon et al., 1999) and several other hippocampal lamina (Alkondon and Albuquerque, 2001). Specifically, the $\alpha 4\beta 2$ nicotinic receptor produces the strongest postsynaptic inhibitory current onto CA1 pyramidal neurons as compared to other nicotinic receptors (Alkondon and Albuquerque, 2001). Recently, our laboratory found that the estrogenic CEE component, $\Delta^{8,9}$ -dehydroestrone, enhanced memory and decreased hippocampal and entorhinal cortex $\alpha 4\beta 2$ nicotinic receptor binding in Ovx rats, effects which correlated with better memory (Talboom et al., 2010). Hence, an estrogen-mediated reduction in hippocampal and entorhinal cortex $\alpha 4\beta 2$ nicotinic receptor expression may lead to a suppression of GABA-mediated inhibition and subsequent cognitive enhancement. Progesterone has also been shown to enhance high affinity choline uptake in several cognitive brain regions, and it can potentiate 17 β -estradiol-mediated increases in ChAT mRNA levels in the basal forebrain of Ovx rats (Gibbs, 1996, 2000a). Progesterone and progestins impact the GABAergic system, which may relate to their effects on cognition (Belelli and Herd, 2003; Braden et al., 2010; Paul and Purdy, 1992; Pazol et al., 2009; Wallis and Luttge, 1980). For example, we found that MPA impaired learning and memory, and altered hippocampal and entorhinal cortex glutamic acid decarboxylase (GAD; the synthesizing enzyme for GABA) concentrations in Ovx rats (Braden et al., 2010). Further, we demonstrated that MPA exposure during either young adulthood, middle-age, or both, produced cognitive detriments, and higher serum levels of MPA were associated with lower levels of GAD in the dorsal hippocampus (Braden et al., 2011). Understanding the possible long-term effects of MPA administration on cognition, and whether there is a subsequent long-term impact on the GABAergic system, is especially relevant as we embark on a new generation of menopausal women who were much more likely to have been prescribed contraceptives when younger, and then HT when older, as compared to generations before (Diczfalusy, 1991).

The mechanism of MPA effects on cognition likely differs from the mechanism of progesterone effects on cognition. There is evidence that MPA's ring-A reduced metabolites (e.g., dihydroMPA and tetrahydroMPA) do not directly bind to the GABA_A receptor (McAuley et al. 1993), as do natural

progesterone's ring-A reduced metabolites (Paul and Purdy, 1992). However, MPA might alter progesterone's metabolic conversions (Penning et al., 1985), which could be related to MPA-induced enhanced synaptic and extrasynaptic GABA_A receptor-mediated inhibition (Belelli and Herd, 2003) and changes in GAD expression (Braden et al., 2010). In fact, the same decrease in GAD levels in the dorsal hippocampus after administration of the GABA_A agonist diazepam (Raol et al. 2005) indicates that MPA-induced decreases in GAD expression are a consequence of increased GABA_A receptor activation.

9.2. Adult neurogenesis

Adult neurogenesis is the process whereby new-born neurons are produced from progenitor cells populations in the adult central nervous system (Ming and Song, 2011). Whether neurogenesis has a functional impact on cognition has yet to be determined. However, the literature thus far indicates that female steroids do, in fact, have an effect on many experimental measures and parameters of neurogenesis. Some very recent studies have evaluated the potential effects that estrogens have on cognitive function. For example, 17 β -estradiol, but not estrone, increased activation of new neurons in the dentate gyrus of young adult Ovx rats in response to the retrieval of spatial memory (McClure et al., 2012). However, the estrogenic-induced differences in this activation of new neurons do not seem to translate into regulation of cognitive behavior, as there were no differences in spatial memory between the treatment groups. Similarly, tonic low dose CEE treatment increased the number of new neurons in the dentate gyrus (Barha and Galea, 2012); however, these rats showed impaired spatial working and reference memory, again indicating that increases in neurogenesis do not necessarily parallel cognitive outcome. These divergent results between an effect on a brain marker versus an effect on cognition underscores the importance of testing the functional outcome of brain changes, as brain changes do not always translate to functional phenotypes such as cognitive changes.

Relative to the number of studies testing the effects of estrogens on neurogenesis, the impact of progesterone on neurogenesis is less studied. Results thus far show that progesterone modulated the effects of 17 β -estradiol on cell proliferation in vivo (see Pawluski et al., 2009), and the progesterone metabolite, allopregnanolone, enhanced cell proliferation in vitro (Wang et al., 2005). Hence, comprehensive evaluations testing the ability of progesterone alone to concurrently induce markers of neurogenesis and alter cognition using in vivo strategies are warranted. It is noteworthy that while female steroid effects on neurogenesis and its relation to cognitive function is a relatively new area of investigation, such interdisciplinary studies are increasing and may unveil exciting new mechanisms of steroid effects on cognition.

9.3. Signaling cascades

The non-classic effects of ovarian steroids influence numerous signal transduction pathways, or signaling cascades, ultimately leading to modulation of protein kinases (reviewed

in Falkenstein et al., 2000). Protein kinases phosphorylate many targets, and the phosphorylation event is usually the last step in a signal transduction cascade that results in a milieu of changes including functional alteration in proteins and modulation of gene transcription (Manning et al., 2002). Some of the kinases influenced by ovarian steroids, and implicated in cognition, are: mitogen-activated protein kinase (MAPK), extracellular-signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K), and the mammalian target of rapamycin (mTOR). MAPK phosphorylates ERK; MAPK and ERK are the final targets of several other kinases including PI3K and Akt (i.e., PKB), and these signaling pathways modulate cognitive processes (e.g., Chen et al., 2005; Fan et al., 2010). For example, ERK activation (i.e., ERK phosphorylation) in the hippocampus is necessary for long-term memory (Kelly et al., 2003). Research has demonstrated that 17 β -estradiol enhances memory via dorsal hippocampal ERK activation in Ovx mice (Fernandez et al., 2008). Indeed, dorsal hippocampal infusions of the MAPK inhibitor (U0126) blocked the memory enhancing effects of intracerebroventricular (i.c.v) infusion of 17 β -estradiol in Ovx mice (Fernandez et al., 2008; Zhao et al., 2010). In addition to 17 β -estradiol, Orr et al. (2009) recently found that dorsal hippocampal infusions of progesterone increased ERK activation and the mTOR substrate S6K in the dorsal hippocampus of Ovx mice; ERK and mTOR activation were necessary for progesterone to facilitate memory. mTOR is a kinase that has effects on cell growth and proliferation via the regulation of protein synthesis (Hay and Sonenberg, 2004). mTOR is activated by ERK (Kelleher et al., 2004; Mendoza et al., 2011; Tsokas et al., 2005), and phosphorylation of 4E-BP1 and S6 in brain is regulated by the ERK pathway, which is known to play a role in synaptic plasticity (Kelleher et al., 2004). Collectively, ERK and mTOR appear to work together to influence synaptic plasticity (Hay and Sonenberg, 2004). 17 β -estradiol has been shown to stimulate MAPK and PI3K via its actions at the once orphaned G-protein coupled receptor 30 (GPR30) and the subsequent transactivation of epidermal growth factor receptors (Prossnitz et al., 2008). Collectively, these studies suggest that some of the cognitive effects of 17 β -estradiol are mediated by GPR30 via signaling through the MAPK and ERK pathways. Furthermore, progesterone appears to enhance object memory via ERK and mTOR, while the mechanism of this effect is still under investigation.

9.4. Epigenetics

Interest in mechanisms through which the activational effects of female steroids are realized has led to multi-scale molecular and genetic investigations. Broadly defined, the epigenome is a collection of heritable modifications (e.g., histone modification and DNA methylation) that alters gene transcription via mechanisms other than modification of the underlying genetic sequence (see Russo et al., 1996). Several studies have demonstrated that histone modification and DNA methylation regulate formation of hippocampal-dependent memories (e.g., Levenson et al., 2004; Miller et al., 2008), and that 17 β -estradiol can mediate epigenetic change (Zhao et al., 2010, 2012). Specifically, 17 β -estradiol, via MAPK/ERK signaling, increases histone acetylation (i.e., histone H3) in the dorsal hippocampus, and this histone modification is

necessary for 17 β -estradiol's memory enhancement in Ovx mice (Zhao et al., 2010, 2012). However, how estrogen-induced modifications in the epigenome generalize to progesterone-induced and androgen-induced modifications is a question for future research. A recent study has shown that, similar to 17 β -estradiol, progesterone activates ERK signaling in the dorsal hippocampus and enhances memory in Ovx mice (Orr et al., 2012), and may therefore similarly modify the epigenome.

10. Hormone receptors and the cognitive effects of hormones

The cognitive effects of steroid hormones discussed thus far are, in part, mediated by distinct expression of receptors in the brain. Since its discovery in 1966, estrogen receptor- α (ER α) was the first, and thought to be the only, member of the nuclear receptor superfamily that exhibits specificity for 17 β -estradiol (Toft and Gorski, 1966). It was not until 30 years later that the second ER subtype, ER β , was discovered (Kuiper et al., 1996). The two ERs share a significant degree of sequence homology; however, they also have important differences in their ligand-binding domain and unique distribution patterns in the brain, suggesting divergent roles of these receptors on biological function (Enmark et al., 1997; Matthews and Gustafsson, 2003; Tremblay et al., 1997). Of note, both ERs are found in brain regions thought to regulate cognitive function, including cerebral cortex and hippocampus (Gonzalez et al., 2007; Mitra et al., 2003; Osterlund et al., 2000; Pau et al., 1998; Register et al., 1998; Shughrue et al., 1997).

A few seminal studies have recently brought to light the importance of assessing changes in expression levels of the ERs as a function of age, as it may reflect transitions in 17 β -estradiol responsiveness of the brain that ultimately lead to cognitive deficits. As aging ensues, 17 β -estradiol responsiveness seems to decline as ER α expression levels decrease in human hippocampus (Ishunina et al., 2007; Tohgi et al., 1995). Similarly, ER α (Adams et al., 2002), but not ER β (Waters et al., 2011), decreases in the hippocampus of aged, compared to young, Ovx rats. Some neurological diseases that affect memory, such as AD, are also associated with decreased ER α and increased ER β expression in the hippocampus (Ishunina et al., 2007; Perlman et al., 2005; Savaskan et al., 2001). Furthermore, ER α polymorphisms are associated with increased incidence of AD among women (Corbo et al., 2006; Ji and Dani, 2000; Olsen et al., 2006; Yaffe et al., 2002, 2009). Collectively, these findings highlight the clinical significance of characterizing the age-related changes in ERs; in particular, the decreased ER α /ER β ratio during aging seems to be associated with cognitive deficits.

These decreases in the ER α /ER β ratio may be age-dependently reversed by 17 β -estradiol. 17 β -estradiol treatment increases ER β , but not ER α , in the hippocampus of aged Ovx rats (Adams et al., 2002; Waters et al., 2011), suggesting that ER β retains 17 β -estradiol responsiveness, while ER α does not. In contrast, 17 β -estradiol increases ER α without affecting ER β expression in the hippocampus of middle-aged ovariectomized rats (Bohacek and Daniel, 2009). This 17 β -estradiol-induced ER α expression is long lasting,

as it is also found in aged Ovx rats that received transient 17 β -estradiol treatment discontinued 7 months prior when middle-aged (Rodgers et al., 2010). Even more provocative is the finding that this prior 17 β -estradiol treatment is also associated with improved memory, suggesting two intriguing tenets. The first is that 17 β -estradiol has a long-term effect on ER α expression and cognitive function. Second, these long-term effects do not require 17 β -estradiol to be on board at the time of cognitive testing. Significant clinical implications can be drawn by these studies, as these reports illustrate that age-related decreases in the ER α /ER β ratio are associated with cognitive dysfunction, both of which can potentially be enhanced permanently by transient exposure to 17 β -estradiol following loss of ovarian function, if initiated earlier in life.

Delineating the individual roles of the ERs on cognition is a considerable challenge; in this regard, ER knockout (ERKO) mice are an invaluable tool. Studies using this model implicate divergent functions of ER α and ER β on cognition, depending on the type of learning and memory evaluated. For example, ER α is important for emotional learning, as performance in the inhibitory avoidance task is impaired in ER α KO mice, but not ER β KO mice (Fugger et al., 2000). In contrast, disruption of ER β , but not ER α , impairs spatial learning on the Morris water maze, suggesting that ER β is required for spatial learning (Fugger et al., 2000; Rissman et al., 2002).

An important caveat must be considered, however, when interpreting these findings. Because ER activity is disrupted throughout development of these ERKO mice, it is difficult to distinguish between organizational and activational effects. Thus, moving forward, it becomes increasingly critical to combine other available tools with the ERKO model to circumvent this confound. Two important studies have capitalized on recent advancements in molecular and pharmacological techniques. First, Foster et al. (2008) used a viral vector-mediated gene transfer to deliver the ER α gene in the ER α KO mice, and found that restoration of ER α in the hippocampus improves spatial learning in Ovx animals. This finding is remarkable, given that this enhanced cognitive function is evident in the absence of 17 β -estradiol treatment. This study also implies that learning deficits observed in ER α KO mice are not only due to organizational effects, but are also likely to be mediated by hippocampal ER α activity in adulthood. Second, Liu et al. (2008) combined the use of the selective estrogen receptor modulators (SERMs) with the ERKO model to show that 17 β -estradiol or a selective ER β , but not ER α , agonist improves spatial memory in wildtype and ER α KO mice, but not ER β KO mice. These results give further credence to the concept that ER β activation during adulthood is pro-cognitive in the spatial domain.

Mounting evidence from studies using SERMs corroborate the idea put forth by the ERKO models that the two ER subtypes regulate distinct learning and memory types. Acute treatment with an ER β , but not ER α , agonist enhances performance in the spatial water maze and on inhibitory avoidance (Rhodes and Frye, 2006), while an ER α , but not ER β , agonist enhances performance in object placement and object recognition (Frye et al., 2007). However, using similar parameters, Jacome et al. (2010) reported opposite findings, implicating ER β in enhanced object placement and object

recognition performance. In this case, the difference in the strain of rats used in the two studies (Long Evans versus Sprague Dawley, respectively) may have contributed to the discrepancies, as other conditions were similar. In general, we must note that species, age, and duration of treatment may also be important factors, as chronic treatment of either ER α or ER β agonists enhances cognition in young rats (Hammond et al., 2009), impair cognition in middle-aged rats (Neese et al., 2010), and has no cognitive effects in adult monkeys (Lacreuse et al., 2009). These studies underscore the complexity of factors involved in using SERMs, and points to the importance of further investigation of potential parameters that impact cognitive outcome.

Prospects of using combined tools to elucidate the distinct functions of ER α and ER β are promising. In recent years, technological advances have flourished in a variety of disciplines, including genetic (i.e., conditional transgenic mice), pharmacological (SERMs), and molecular (gene transfer and antisense oligonucleotides) avenues for region- and time-specific manipulation of the ERs. Thus, we are at a pivotal point where it is now possible to resolve some of the key obstacles that have stymied the field. By embracing these seemingly confounding factors and exploiting all available tools in a multi-disciplined manner, we can advance our knowledge of the roles of these receptors on cognitive function.

11. General conclusions

Gonadal hormones have activational effects on cognition. Interest in elucidating the factors that mediate these effects has intensified over the last decade. Notably, this heightened interest is within the realm of both the depth and breadth of the impact that ovarian hormones might exert on cognition. Of these effects, the significance of age-related cognitive decline, and how it may be exacerbated by concurrent gonadal hormone loss, has been an increasingly prominent area of focus in female rodents and in women. Efforts have recently been made to restore balance of the hormonal milieu in an attempt to ameliorate age-related cognitive deficits. The clinical and basic science literature has presented many elegant, methodically controlled, clearly interpretable experiments to better understand the parameters that govern the profound consequences of hormone loss and hormone treatment on cognition and brain health. Animal models have served as a valuable tool in characterizing the parameters that might lead to clinical intervention, and will be key to future discoveries. Researchers have identified some intricate relationships between these factors by understanding their individual contributions on cognition. This type of systematic approach has guided much of the discoveries in the field, including the differential cognitive effects of estrogens, progestogens, and androgens. Indeed, the timing, route, dose, and duration of administration are also important factors to consider. Research is now moving to understanding the effects of these variables in concert, as well as interactions between different types of hormones when administered concomitantly. This knowledge is key to translating preclinical data to the clinic, wherein women typically have exposure to endogenous ovarian hormones, and also take combination HTs concurrently. An

overview of the existing literature on the impact of HT on cognition might seem controversial, but when taking these variables into account, we can appreciate the multitude of considerations involved in optimizing treatment for menopause. We are now in an exciting time when technological advances in the field of neuroscience are meeting the demands and enthusiasm of scientists who wish to better understand hormone effects on the brain and cognition. Many interdisciplinary scientists now perform animal studies with a clinically-driven experimental design, which is key to discoveries of a translational nature. In this domain, the holy grail is to use these discoveries to expand the window of opportunity to ultimately enhance cognition in aging women.

REFERENCES

- Acosta, J.I., Mayer, L., Talboom, J.S., Tsang, C.W., Smith, C.J., Enders, C.K., Bimonte-Nelson, H.A., 2009a. Transitional versus surgical menopause in a rodent model: etiology of ovarian hormone loss impacts memory and the acetylcholine system. *Endocrinology*.
- Acosta, J.I., Mayer, L., Talboom, J.S., Zay, C., Scheldrup, M., Castillo, J., Demers, L.M., Enders, C.K., Bimonte-Nelson, H.A., 2009b. Premarin improves memory, prevents scopolamine-induced amnesia and increases number of basal forebrain choline acetyltransferase positive cells in middle-aged surgically menopausal rats. *Horm. Behav.* 55, 454–464.
- Acosta, J.I., Mayer, L.P., Braden, B.B., Nonnenmacher, S., Mennenga, S.E., Bimonte-Nelson, H.A., 2010. The cognitive effects of conjugated equine estrogens depend on whether menopause etiology is transitional or surgical. *Endocrinology* 151, 3795–3804.
- Adams, M.M., Fink, S.E., Shah, R.A., Janssen, W.G., Hayashi, S., Milner, T.A., McEwen, B.S., Morrison, J.H., 2002. Estrogen and aging affect the subcellular distribution of estrogen receptor-alpha in the hippocampus of female rats. *J. Neurosci.* 22, 3608–3614.
- Aggleton, J.P., Blindt, H.S., Candy, J.M., 1989. Working memory in aged rats. *Behav. Neurosci.* 103, 975–983.
- Aguirre, C.C., Baudry, M., 2009. Progesterone reverses 17beta-estradiol-mediated neuroprotection and BDNF induction in cultured hippocampal slices. *Eur. J. Neurosci* 29, 447–454.
- Alkondon, M., Pereira, E.F., Eisenberg, H.M., Albuquerque, E.X., 1999. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. *J. Neurosci* 19, 2693–2705.
- Alkondon, M., Albuquerque, E.X., 2001. Nicotinic acetylcholine receptor alpha7 and alpha4beta2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. *J. Neurophysiol* 86, 3043–3055.
- Alliot, J., Nauton, P., Bruhat, M.A., 1993. Administration of LHRH analog can improve working memory in aged female rats. *Psychoneuroendocrinology* 18, 543–550.
- Amundsen, D.W., Diers, C.J., 1970. The age of menopause in classical Greece and Rome. *Hum. Biol.* 42, 79–86.
- Amundsen, D.W., Diers, C.J., 1973. The age of menopause in medieval Europe. *Hum. Biol.* 45, 605–612.
- Arnold, A.P., Breedlove, S.M., 1985. Organizational and activation effects of sex steroids on brain and behavior: a reanalysis. *Horm. Behav.* 19, 469–498.
- Asthana, S., Craft, S., Baker, L.D., Raskind, M.A., Birnbaum, R.S., Lofgreen, C.P., Veith, R.C., Plymate, S.R., 1999. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. *Psychoneuroendocrinology* 24, 657–677.
- Asthana, S., Baker, L.D., Craft, S., Stanczyk, F.Z., Veith, R.C., Raskind, M.A., Plymate, S.R., 2001. High-dose estradiol improves cognition for women with AD: results of a randomized study. *Neurology* 57, 605–612.
- Baddeley, A.D., Hitch, G.J., 1974. Working memory. In: Bower, G.A. (Ed.), *The psychology of learning and motivation: Advances in research and theory*, Vol. 8. Academic Press, New York, NY, pp. 47–90.
- Balota, D.A., Dolan, P.O., Duchek, J.M., 2000. Memory changes in healthy young and older adults. In: Tulving, E., Craik, F.I.M. (Eds.), *Handbook of Memory*. Vol. Oxford University Press, pp. 395–410.
- Barha, C.K., Galea, L.A., 2012. The hormone therapy, premarin, impairs hippocampus-dependent spatial learning and memory and reduces activation of new granule neurons in response to memory in female rats. *Neurobiol. Aging*.
- Barnes, C.A., 1998. Memory changes during normal aging: Neurobiological correlates. In: Martinez Jr., J.A., Kesner, R.P. (Eds.), *Neurobiology of Learning and Memory*. Academic Press, San Diego, CA, pp. 247–273.
- Beach, F.A., 1947. Hormones and mating behaviors in vertebrates. In: *Recent Progress in Hormone Research*. Academic Press, New York, NY.
- Beatty, W.W., Beatty, P.A., 1970. Hormonal determinants of sex differences in avoidance behavior and reactivity to electric shock in the rat. *J. Comp. Physiol. Psychol* 73, 446–455.
- Beatty, W.W. (Ed.), 1992. *Gonadal hormones and sex differences in nonreproductive behaviors*. Plenum Press, New York.
- Becker, J.B., Cha, J.H., 1989. Estrous cycle-dependent variation in amphetamine-induced behaviors and striatal dopamine release assessed with microdialysis. *Behav. Brain. Res* 35, 117–125.
- Becker, K., 1995. *Principles and Practice of Endocrinology and Metabolism*. J. B. Lippincott Co., Philadelphia.
- Belelli, D., Herd, M.B., 2003. The contraceptive agent Provera enhances GABA(A) receptor-mediated inhibitory neurotransmission in the rat hippocampus: evidence for endogenous neurosteroids? *J. Neurosci* 23, 10013–10020.
- Benice, T.S., Raber, J., 2009. Testosterone and dihydrotestosterone differentially improve cognition in aged female mice. *Learn. Memory* 16, 479–485.
- Berry, B., McMahan, R., Gallagher, M., 1997. Spatial learning and memory at defined points of the estrous cycle: effects on performance of a hippocampal-dependent task. *Behav. Neurosci* 111, 267–274.
- Bhavnani, B.R., 2003. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. *J. Steroid Biochem. Mol. Biol* 85, 473–482.
- Bimonte-Nelson, H.A., Singleton, R.S., Hunter, C.L., Price, K.L., Moore, A.B., Granholm, A.C.E., 2003. Ovarian hormones and cognition in the aged female rat: I. Long-term, but not short-term, ovariectomy enhances spatial performance. *Behav. Neurosci.* 117, 1395–1406.
- Bimonte-Nelson, H.A., Nelson, M.E., Granholm, A.C., 2004a. Progesterone counteracts estrogen-induced increases in neurotrophins in the aged female rat brain. *Neuroreport* 15, 2659–2663.
- Bimonte-Nelson, H.A., Singleton, R.S., Williams, B.J., Granholm, A.C.E., 2004b. Ovarian hormones and cognition in the aged female rat: II. progesterone supplementation reverses the cognitive enhancing effects of ovariectomy. *Behav. Neurosci.* 118, 707–714.
- Bimonte-Nelson, H.A., Francis, K.R., Umphlet, C.D., Granholm, A.C., 2006. Progesterone reverses the spatial memory enhancements initiated by tonic and cyclic oestrogen therapy

- in middle-aged ovariectomized female rats. *Eur. J. Neurosci* 24, 229–242.
- Bimonte-Nelson, H.A., Acosta, J.I., Talboom, J.S., 2010. Neuroscientists as cartographers: mapping the crossroads of gonadal hormones, memory and age using animal models. *Molecules* 15, 6050–6105.
- Bimonte, H.A., Denenberg, V.H., 1999. Estradiol facilitates performance as working memory load increases. *Psychoneuroendocrinology* 24, 161–173.
- Bimonte, H.A., Fitch, R.H., Denenberg, V.H., 2000a. Neonatal estrogen blockade prevents normal callosal responsiveness to estradiol in adulthood. *Brain Res. Dev. Brain Res.* 122, 149–155.
- Bimonte, H.A., Holly Fitch, R., Denenberg, V.H., 2000b. Adult ovary transfer counteracts the callosal enlargement resulting from prepubertal ovariectomy. *Brain Res.* 872, 254–257.
- Bimonte, H.A., Mack, C.M., Stavnezer, A.J., Denenberg, V.H., 2000c. Ovarian hormones can organize the rat corpus callosum in adulthood. *Brain Res. Dev. Brain Res.* 121, 169–177.
- Bimonte, H.A., Nelson, M.E., Granholm, A.C., 2003. Age-related deficits as working memory load increases: relationships with growth factors. *Neurobiol. Aging* 24, 37–48.
- Birzniece, V., Turkmen, S., Lindblad, C., Zhu, D., Johansson, I.M., Backstrom, T., Wahlstrom, G., 2006. GABA(A) receptor changes in acute allopregnanolone tolerance. *Eur. J. Pharmacol.* 535, 125–134.
- Bloch, G.J., Gorski, R.A., 1988. Estrogen/progesterone treatment in adulthood affects the size of several components of the medial preoptic area in the male rat. *J. Comp. Neurol.* 275, 613–622.
- Bohacek, J., Bearl, A.M., Daniel, J.M., 2008. Long-term ovarian hormone deprivation alters the ability of subsequent oestradiol replacement to regulate choline acetyltransferase protein levels in the hippocampus and prefrontal cortex of middle-aged rats. *J. Neuroendocrinol* 20, 1023–1027.
- Bohacek, J., Daniel, J.M., 2009. The ability of oestradiol administration to regulate protein levels of oestrogen receptor alpha in the hippocampus and prefrontal cortex of middle-aged rats is altered following long-term ovarian hormone deprivation. *J. Neuroendocrinol* 21, 640–647.
- Bowen, R.L., Verdile, G., Liu, T., Parlow, A.F., Perry, G., Smith, M.A., Martins, R.N., Atwood, C.S., 2004. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. *J. Biol. Chem.* 279, 20539–20545.
- Braden, B.B., Talboom, J.S., Crain, I.D., Simard, A.R., Lukas, R.J., Prokai, L., Scheldrup, M.R., Bowman, B.L., Bimonte-Nelson, H.A., 2010. Medroxyprogesterone acetate impairs memory and alters the GABAergic system in aged surgically menopausal rats. *Neurobiol. Learn. Mem.* 93, 444–453.
- Braden, B.B., Garcia, A.N., Mennenga, S.E., Prokai, L., Villa, S.R., Acosta, J.I., Lefort, N., Simard, A.R., Bimonte-Nelson, H.A., 2011. Cognitive-impairing effects of medroxyprogesterone acetate in the rat: independent and interactive effects across time. *Psychopharmacology (Berl)* 218, 405–418.
- Brett, M., Baxendale, S., 2001. Motherhood and memory: a review. *Psychoneuroendocrinology* 26, 339–362.
- Caldwell, B.M., Watson, R.I., 1952. An evaluation of psychological effects of sex hormone administration in aged women. I. Results of therapy after six months. *J. Gerontol* 7, 228–244.
- Camp, B.W., Gerson, J.E., Tsang, C.W., Villa, S.R., Acosta, J.I., Blair Braden, B., Hoffman, A.N., Conrad, C.D., Bimonte-Nelson, H.A., 2012. High serum androstenedione levels correlate with impaired memory in the surgically menopausal rat: a replication and new findings. *Eur. J. Neurosci.* 36, 3086–3095.
- Campbell, S., Whitehead, M., 1977. Oestrogen therapy and the menopausal syndrome. *Clin. Obstet. Gynaecol* 4, 31–47.
- Casadesus, G., Webber, K.M., Atwood, C.S., Pappolla, M.A., Perry, G., Bowen, R.L., Smith, M.A., 2006. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. *Biochim. Biophys. Acta.* 1762, 447–452.
- Casadesus, G., Milliken, E.L., Webber, K.M., Bowen, R.L., Lei, Z., Rao, C.V., Perry, G., Keri, R.A., Smith, M.A., 2007. Increases in luteinizing hormone are associated with declines in cognitive performance. *Mol. Cell Endocrinol.* 269, 107–111.
- Chen, X., Garelick, M.G., Wang, H., Lil, V., Athos, J., Storm, D.R., 2005. PI3 kinase signaling is required for retrieval and extinction of contextual memory. *Nat. Neurosci.* 8, 925–931.
- Chesler, E.J., Juraska, J.M., 2000. Acute administration of estrogen and progesterone impairs the acquisition of the spatial morris water maze in ovariectomized rats. *Horm. Behav.* 38, 234–242.
- Chisholm, N.C., Juraska, J.M., 2012. Long-term replacement of estrogen in combination with medroxyprogesterone acetate improves acquisition of an alternation task in middle-aged female rats. *Behav. Neurosci.* 126, 128–136.
- Coker, L.H., Espeland, M.A., Rapp, S.R., Legault, C., Resnick, S.M., Hogan, P., Gaussoin, S., Dailey, M., Shumaker, S.A., 2010. Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS). *J. Steroid. Biochem. Mol. Biol.* 118, 304–310.
- Conrad, C.D., Bimonte-Nelson, H.A., 2010. Impact of the hypothalamic-pituitary-adrenal/gonadal axes on trajectory of age-related cognitive decline. *Prog. Brain Res.* 182, 31–76.
- Corbo, R.M., Gambina, G., Ruggeri, M., Scacchi, R., 2006. Association of estrogen receptor alpha (ESR1) PvuII and XbaI polymorphisms with sporadic Alzheimer's disease and their effect on apolipoprotein E concentrations. *Dement. Geriatr. Cogn. Disord.* 22, 67–72.
- Daniel, J.M., Fader, A.J., Spencer, A.L., Dohanich, G.P., 1997. Estrogen enhances performance of female rats during acquisition of a radial arm maze. *Horm. Behav.* 32, 217–225.
- Daniel, J.M., Roberts, S.L., Dohanich, G.P., 1999. Effects of ovarian hormones and environment on radial maze and water maze performance of female rats. *Physiol. Behav.* 66, 11–20.
- Daniel, J.M., Dohanich, G.P., 2001. Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory. *J. Neurosci.* 21, 6949–6956.
- Daniel, J.M., Hulst, J.L., Lee, C.D., 2005. Role of hippocampal M2 muscarinic receptors in the estrogen-induced enhancement of working memory. *Neuroscience* 132, 57–64.
- Daniel, J.M., Sulzer, J.K., Hulst, J.L., 2006. Estrogen increases the sensitivity of ovariectomized rats to the disruptive effects produced by antagonism of D2 but not D1 dopamine receptors during performance of a response learning task. *Horm. Behav.* 49, 38–44.
- Dohanich, G.P., Fader, A.J., Javorsky, D.J., 1994. Estrogen and estrogen-progesterone treatments counteract the effect of scopolamine on reinforced T-maze alternation in female rats. *Behav. Neurosci.* 108, 988–992.
- Downs, J.L., Wise, P.M., 2009. The role of the brain in female reproductive aging. *Mol. Cell Endocrinol.* 299, 32–38.
- El-Bakri, N.K., Islam, A., Zhu, S., Elhassan, A., Mohammed, A., Winblad, B., Adem, A., 2004. Effects of estrogen and progesterone treatment on rat hippocampal NMDA receptors: relationship to Morris water maze performance. *J. Cell. Mol. Med.* 8, 537–544.
- Engler-Chiurazzi, E., Tsang, C., Nonnenmacher, S., Liang, W.S., Corneveaux, J.J., Prokai, L., Huentelman, M.J., Bimonte-Nelson, H.A., 2011. Tonic Premarin dose-dependently enhances memory, affects neurotrophin protein levels and alters gene expression in middle-aged rats. *Neurobiol. Aging.* 32, 680–697.
- Engler-Chiurazzi, E.B., Talboom, J.S., Braden, B.B., Tsang, C.W., Mennenga, S., Andrews, M., Demers, L.M., Bimonte-Nelson,

- H.A., 2012. Continuous estrone treatment impairs spatial memory and does not impact number of basal forebrain cholinergic neurons in the surgically menopausal middle-aged rat. *Horm. Behav.* 62, 1–9.
- Enmark, E., Peltö-Huikko, M., Grandien, K., Lagercrantz, S., Lagercrantz, J., Fried, G., Nordenskjöld, M., Gustafsson, J.A., 1997. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. *J. Clin. Endocrinol. Metab.* 82, 4258–4265.
- Espeland, M.A., Rapp, S.R., Shumaker, S.A., Brunner, R., Manson, J.E., Sherwin, B.B., Hsia, J., Margolis, K.L., Hogan, P.E., Wallace, R., Dailey, M., Freeman, R., Hays, J., 2004. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative memory study. *JAMA* 291, 2959–2968.
- Falkenstein, E., Tillmann, H.C., Christ, M., Feuring, M., Wehling, M., 2000. Multiple actions of steroid hormones—a focus on rapid, nongenomic effects. *Pharmacol. Rev.* 52, 513–556.
- Fan, L., Zhao, Z., Orr, P.T., Chambers, C.H., Lewis, M.C., Frick, K.M., 2010. Estradiol-induced object memory consolidation in middle-aged female mice requires dorsal hippocampal extracellular signal-regulated kinase and phosphatidylinositol 3-kinase activation. *J. Neurosci.* 30, 4390–4400.
- Farrag, A.K., Khedr, E.M., Abdel-Aleem, H., Rageh, T.A., 2002. Effect of surgical menopause on cognitive functions. *Dement. Geriatr. Cogn. Disord.* 13, 193–198.
- Feng, Z., Cheng, Y., Zhang, J.T., 2004. Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats. *J. Pineal. Res.* 37, 198–206.
- Fernandez, S.M., Lewis, M.C., Pechenino, A.S., Harburger, L.L., Orr, P.T., Gresack, J.E., Schafe, G.E., Frick, K.M., 2008. Estradiol-induced enhancement of object memory consolidation involves hippocampal extracellular signal-regulated kinase activation and membrane-bound estrogen receptors. *J. Neurosci.* 28, 8660–8667.
- Fitch, R.H., Denenberg, V.H., 1998. A role for ovarian hormones in sexual differentiation of the brain. *Behav. Brain Sci.* 21, 311–327 discussion 327–52.
- Foster, T.C., Sharrow, K.M., Kumar, A., Masse, J., 2003. Interaction of age and chronic estradiol replacement on memory and markers of brain aging. *Neurobiol. Aging* 24, 839–852.
- Foster, T.C., Rani, A., Kumar, A., Cui, L., Semple-Rowland, S.L., 2008. Viral vector-mediated delivery of estrogen receptor-alpha to the hippocampus improves spatial learning in estrogen receptor-alpha knockout mice. *Mol. Ther.* 16, 1587–1593.
- Frankfurt, M., Gould, E., Woolley, C.S., McEwen, B.S., 1990. Gonadal steroids modify dendritic spine density in ventromedial hypothalamic neurons: a Golgi study in the adult rat. *Neuroendocrinology* 51, 530–535.
- Freeman, E.W., Weinstock, L., Rickels, K., Sondheimer, S.J., Coutifaris, C., 1992. A placebo-controlled study of effects of oral progesterone on performance and mood. *Br. J. Clin. Pharmacol.* 33, 293–298.
- Frick, K.M., Fernandez, S.M., Bulinski, S.C., 2002. Estrogen replacement improves spatial reference memory and increases hippocampal synaptophysin in aged female mice. *Neuroscience* 115, 547–558.
- Frye, C.A., Lacey, E.H., 2001. Posttraining androgens' enhancement of cognitive performance is temporally distinct from androgens' increases in affective behavior. *Cogn. Affect. Behav. Neurosci.* 1, 172–182.
- Frye, C.A., Duffy, C.K., Walf, A.A., 2007. Estrogens and progestins enhance spatial learning of intact and ovariectomized rats in the object placement task. *Neurobiol. Learn. Mem.* 88, 208–216.
- Fugger, H.N., Foster, T.C., Gustafsson, J., Rissman, E.F., 2000. Novel effects of estradiol and estrogen receptor alpha and beta on cognitive function. *Brain Res.* 883, 258–264.
- Gabriel, A., Fahim, G., 2005. Do depot medroxyprogesterone acetate contraceptive injections cause mood changes and memory impairment? *Prim. Psychiatry* 12, 59–60.
- Galea, L.A., Wide, J.K., Paine, T.A., Holmes, M.M., Ormerod, B.K., Floresco, S.B., 2001. High levels of estradiol disrupt conditioned place preference learning, stimulus response learning and reference memory but have limited effects on working memory. *Behav. Brain Res.* 126, 115–126.
- Gibbs, R.B., Wu, D., Hersh, L.B., Pfaff, D.W., 1994. Effects of estrogen replacement on the relative levels of choline acetyltransferase, trkA, and nerve growth factor messenger RNAs in the basal forebrain and hippocampal formation of adult rats. *Exp. Neurol.* 129, 70–80.
- Gibbs, R.B., 1996. Fluctuations in relative levels of choline acetyltransferase mRNA in different regions of the rat basal forebrain across the estrous cycle: effects of estrogen and progesterone. *J. Neurosci.* 16, 1049–1055.
- Gibbs, R.B., 2000a. Effects of gonadal hormone replacement on measures of basal forebrain cholinergic function. *Neuroscience* 101, 931–938.
- Gibbs, R.B., 2000b. Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. *Neurobiol. Aging* 21, 107–116.
- Gibbs, R.B., 2002. Basal forebrain cholinergic neurons are necessary for estrogen to enhance acquisition of a delayed matching-to-position T-maze task. *Horm. Behav.* 42, 245–257.
- Gibbs, R.B., 2007. Estradiol enhances DMP acquisition via a mechanism not mediated by turning strategy but which requires intact basal forebrain cholinergic projections. *Horm. Behav.* 52, 352–359.
- Gibbs, R.B., Johnson, D.A., 2008. Sex-specific effects of gonadectomy and hormone treatment on acquisition of a 12-arm radial maze task by Sprague Dawley rats. *Endocrinology* 149, 3176–3183.
- Gibbs, R.B., Chipman, A.M., Hammond, R., Nelson, D., 2011a. Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats. *Horm. Behav.* 60, 607–616.
- Gibbs, R.B., Chipman, A.M., Nelson, D., 2011b. Donepezil plus estradiol treatment enhances learning and delay-dependent memory performance by young ovariectomized rats with partial loss of septal cholinergic neurons. *Horm. Behav.* 59, 503–511.
- Goldman-Rakic, P.S., 1987. Circuitry of primate prefrontal cortex and the regulation of behavior by representational memory. In: *Handbook of Physiology*, vol 5 (1). American Physiological Society, Bethesda, MD.
- Gomez-Gil, E., Canizares, S., Torres, A., de la Torre, F., Halperin, I., Salamero, M., 2009. Androgen treatment effects on memory in female-to-male transsexuals. *Psychoneuroendocrinology* 34, 110–117.
- Gonzalez, M., Cabrera-Socorro, A., Perez-Garcia, C.G., Fraser, J.D., Lopez, F.J., Alonso, R., Meyer, G., 2007. Distribution patterns of estrogen receptor alpha and beta in the human cortex and hippocampus during development and adulthood. *J. Comp. Neurol.* 503, 790–802.
- Gouchie, C., Kimura, D., 1991. The relationship between testosterone levels and cognitive ability patterns. *Psychoneuroendocrinology* 16, 323–334.
- Greendale, G.A., Wight, R.G., Huang, M.H., Avis, N., Gold, E.B., Joffe, H., Seeman, T., Vuge, M., Karlamangla, A.S., 2010. Menopause-associated symptoms and cognitive performance: Results from the study of Women's Health Across the Nation. *Am. J. Epidemiol.* 171, 1214–1224.

- Halbreich, U., Lumley, L.A., Palter, S., Manning, C., Gengo, F., Joe, S.H., 1995. Possible acceleration of age effects on cognition following menopause. *J. Psychiatr. Res.* 29, 153–163.
- Hammond, R., Mauk, R., Ninaci, D., Nelson, D., Gibbs, R.B., 2009. Chronic treatment with estrogen receptor agonists restores acquisition of a spatial learning task in young ovariectomized rats. *Horm. Behav.* 56, 309–314.
- Harburger, L.L., Bennett, J.C., Frick, K.M., 2007. Effects of estrogen and progesterone on spatial memory consolidation in aged females. *Neurobiol. Aging* 28, 602–610.
- Hay, N., Sonenberg, N., 2004. Upstream and downstream of mTOR. *Genes Dev.* 18, 1926–1945.
- Henderson, V.W., 2008. Cognitive changes after menopause: influence of estrogen. *Clin. Obstet. Gynecol.* 51, 618–626.
- Hersh, A.L., Stefanick, M.L., Stafford, R.S., 2004. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. *JAMA* 291, 47–53.
- Holmes, M.M., Wide, J.K., Galea, L.A., 2002. Low levels of estradiol facilitate, whereas high levels of estradiol impair, working memory performance on the radial arm maze. *Behav. Neurosci.* 116, 928–934.
- Huang, H.H., Steger, R.W., Bruni, J.F., Meites, J., 1978. Patterns of sex steroid and gonadotropin secretion in aging female rats. *Endocrinology* 103, 1855–1859.
- Ishunina, T.A., Fischer, D.F., Swaab, D.F., 2007. Estrogen receptor alpha and its splice variants in the hippocampus in aging and Alzheimer's disease. *Neurobiol. Aging* 28, 1670–1681.
- Jacome, L.F., Gautreaux, C., Inagaki, T., Mohan, G., Alves, S., Lubbers, L.S., Luine, V., 2010. Estradiol and ERbeta agonists enhance recognition memory, and DPN, an ERbeta agonist, alters brain monoamines. *Neurobiol. Learn. Mem.* 94, 488–498.
- Ji, D., Dani, J.A., 2000. Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. *J. Neurophysiol.* 83, 2682–2690.
- Kantor, H.I., Michael, C.M., Shore, H., 1973. Estrogen for older women. *Am. J. Obstet. Gynecol.* 116, 115–118.
- Kelleher 3rd, R.J., Govindarajan, A., Jung, H.Y., Kang, H., Tonegawa, S., 2004. Translational control by MAPK signaling in long-term synaptic plasticity and memory. *Cell* 116, 467–479.
- Kelly, A., Laroche, S., Davis, S., 2003. Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase in hippocampal circuitry is required for consolidation and reconsolidation of recognition memory. *J. Neurosci.* 23, 5354–5360.
- Khoo, S.K., O'Neill, S., Byrne, G., King, R., Travers, C., Tripcony, L., 2010. Postmenopausal hormone therapy and cognition: effects of timing and treatment type. *Climacteric* 13, 259–264.
- Kimura, D., Hampson, E., 1994. Cognitive pattern in men and women is influenced by fluctuations in sex hormones. *Psychol. Sci.* 3, 57–61.
- Kritz-Silverstein, D., Barrett-Connor, E., 2002. Hysterectomy, oophorectomy, and cognitive function in older women. *J. Am. Geriatr. Soc.* 50, 55–61.
- Kuhl, H., 2005. Pharmacology of estrogens and progestogens: influence of different routes of administration. *Climacteric* 8 (Suppl 1), 3–63.
- Kuiper, G.G., Enmark, E., Peltö-Huikko, M., Nilsson, S., Gustafsson, J.A., 1996. Cloning of a novel receptor expressed in rat prostate and ovary. *Proc. Natl. Acad. Sci. USA* 93, 5925–5930.
- Lacourse, A., Wilson, M.E., Herndon, J.G., 2009. No effect of different estrogen receptor ligands on cognition in adult female monkeys. *Physiol. Behav.* 96, 448–456.
- Lebrun, C., Durkin, T.P., Marighetto, A., Jaffard, R., 1990. A comparison of the working memory performances of young and aged mice combined with parallel measures of testing and drug-induced activations of septo-hippocampal and nbm-cortical cholinergic neurones. *Neurobiol. Aging* 11, 515–521.
- Lei, Z.M., Rao, C.V., Kornyei, J.L., Licht, P., Hiatt, E.S., 1993. Novel expression of human chorionic gonadotropin/luteinizing hormone receptor gene in brain. *Endocrinology* 132, 2262–2270.
- Levenson, J.M., O'Riordan, K.J., Brown, K.D., Trinh, M.A., Molfese, D.L., Sweatt, J.D., 2004. Regulation of histone acetylation during memory formation in the hippocampus. *J. Biol. Chem.* 279, 40545–40559.
- Lewis, M.C., Kerr, K.M., Orr, P.T., Frick, K.M., 2008. Estradiol-induced enhancement of object memory consolidation involves NMDA receptors and protein kinase A in the dorsal hippocampus of female C57BL/6 mice. *Behav. Neurosci.* 122, 716–721.
- Liu, F., Day, M., Muniz, L.C., Bitran, D., Arias, R., Revilla-Sanchez, R., Grauer, S., Zhang, G., Kelley, C., Pulito, V., Sung, A., Mervis, R.F., Navarra, R., Hirst, W.D., Reinhart, P.H., Marquis, K.L., Moss, S.J., Pangalos, M.N., Brandon, N.J., 2008. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. *Nat. Neurosci.* 11, 334–343.
- Lowry, N.C., Pardon, L.P., Yates, M.A., Juraska, J.M., 2010. Effects of long-term treatment with 17 beta-estradiol and medroxyprogesterone acetate on water maze performance in middle aged female rats. *Horm. Behav.* 58, 200–207.
- Lu, K.H., Hopper, B.R., Vargo, T.M., Yen, S.S., 1979. Chronological changes in sex steroid, gonadotropin and prolactin secretions in aging female rats displaying different reproductive states. *Biol. Reprod.* 21, 193–203.
- Lu, S.F., McKenna, S.E., Cologer-Clifford, A., Nau, E.A., Simon, N.G., 1998. Androgen receptor in mouse brain: sex differences and similarities in autoregulation. *Endocrinology* 139, 1594–1601.
- Luetters, C., Huang, M.H., Seeman, T., Buckwalter, G., Meyer, P.M., Avis, N.E., Sternfeld, B., Johnston, J.M., Greendale, G.A., 2007. Menopause transition stage and endogenous estradiol and follicle-stimulating hormone levels are not related to cognitive performance: cross-sectional results from the study of women's health across the nation (SWAN). *J. Women's Health* 16, 331–344.
- Luine, V.N., McEwen, B.S., 1983. Sex differences in cholinergic enzymes of diagonal band nuclei in the rat preoptic area. *Neuroendocrinology* 36, 475–482.
- Luine, V.N., 1985. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. *Exp. Neurol.* 89, 484–490.
- Luine, V.N., Richards, S.T., Wu, V.Y., Beck, K.D., 1998. Estradiol enhances learning and memory in a spatial memory task and effects levels of monoaminergic neurotransmitters. *Horm. Behav.* 34, 149–162.
- Luine, V.N., Jacome, L.F., Maclusky, N.J., 2003. Rapid enhancement of visual and place memory by estrogens in rats. *Endocrinology* 144, 2836–2844.
- Lukacs, H., Hiatt, E.S., Lei, Z.M., Rao, C.V., 1995. Peripheral and intracerebroventricular administration of human chorionic gonadotropin alters several hippocampus-associated behaviors in cycling female rats. *Horm. Behav.* 29, 42–58.
- Maki, P.M., Henderson, V.W., 2012. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. *Climacteric* 15, 256–262.
- Manning, G., Whyte, D.B., Martinez, R., Hunter, T., Sudarsanam, S., 2002. The protein kinase complement of the human genome. *Science* 298, 1912–1934.
- Markham, J.A., Pych, J.C., Juraska, J.M., 2002. Ovarian hormone replacement to aged ovariectomized female rats benefits acquisition of Morris water maze. *Horm. Behav.* 42, 284–293.

- Markowska, Savonenko, A.V., 2002. Effectiveness of estrogen replacement in restoration of cognitive function after long-term estrogen withdrawal in aging rats. *J. Neurosci.* 22, 10985–10995.
- Marriott, L.K., Korol, D.L., 2003. Short-term estrogen treatment in ovariectomized rats augments hippocampal acetylcholine release during place learning. *Neurobiol. Learn. Mem.* 80, 315–322.
- Matthews, J., Gustafsson, J.A., 2003. Estrogen signaling: a subtle balance between ER alpha and ER beta. *Mol. Interv.* 3, 281–292.
- Mayer, L.P., Pearsall, N.A., Christian, P.J., Devine, P.J., Payne, C.M., McCuskey, M.K., Marion, S.L., Sipes, I.G., Hoyer, P.B., 2002. Long-term effects of ovarian follicular depletion in rats by 4-vinylcyclohexene diepoxide. *Reprod. Toxicol.* 16, 775–781.
- Mayer, L.P., Devine, P.J., Dyer, C.A., Hoyer, P.B., 2004. The follicle-deplete mouse ovary produces androgen. *Biol. Reprod.* 71, 130–138.
- McAuley, J.W., Kroboth, P.D., Stiff, D.D., Reynolds, I.J., 1993. Modulation of [3H]flunitrazepam binding by natural and synthetic progestational agents. *Pharmacol. Biochem. Behav.* 45, 77–83.
- McClure, R.E., Barha, C.K., Galea, L.A., 2012. 17beta-Estradiol, but not estrone, increases the survival and activation of new neurons in the hippocampus in response to spatial memory in adult female rats. *Horm. Behav.*
- McLaughlin, K.J., Bimonte-Nelson, H.A., Neisewander, J.L., Conrad, C.D., 2008. Assessment of estradiol influence on spatial tasks and hippocampal CA1 spines: Evidence that the duration of hormone deprivation after ovariectomy compromises 17β-estradiol effectiveness in altering CA1 spines. *Horm. Behav.* 54, 386–395.
- McMillan, P.J., Singer, C.A., Dorsa, D.M., 1996. The effects of ovariectomy and estrogen replacement on trkA and choline acetyltransferase mRNA expression in the basal forebrain of the adult female Sprague-Dawley rat. *J. Neurosci.* 16, 1860–1865.
- McPhaul, M.J., Young, M., 2001. Complexities of androgen action. *J. Am. Acad. Dermatol.* 45, S87–S94.
- Meites, J., Lu, J.K.H., 1994. Reproductive aging and neuroendocrine function. In: Charlton, H.M. (Ed.), *Oxford review of reproductive biology*, Vol. 16. Oxford Press, New York.
- Mendoza, M.C., Er, E.E., Blenis, J., 2011. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. *Trends Biochem. Sci.* 36, 320–328.
- Miller, C.A., Campbell, S.L., Sweatt, J.D., 2008. DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. *Neurobiol. Learn. Mem.* 89, 599–603.
- Ming, G.L., Song, H., 2011. Adult neurogenesis in the mammalian brain: significant answers and significant questions. *Neuron* 70, 687–702.
- Mitra, S.W., Hoskin, E., Yudkovitz, J., Pear, L., Wilkinson, H.A., Hayashi, S., Pfaff, D.W., Ogawa, S., Rohrer, S.P., Schaeffer, J.M., McEwen, B.S., Alves, S.E., 2003. Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. *Endocrinology* 144, 2055–2067.
- Nappi, R.E., Sinforiani, E., Mauri, M., Bono, G., Polatti, F., Nappi, G., 1999. Memory functioning at menopause: impact of age in ovariectomized women. *Gynecol Obstet Invest.* 47, 29–36.
- Nauton, P., Giry, N., Bruhat, M.A., Alliot, J., 1992. Effect of administration of an analog of LHRH on appetitive learning in young and middle-aged female rats. *Pharmacol. Biochem. Behav.* 43, 1005–1013.
- Neave, N., Menaged, M., Weightman, D.R., 1999. Sex differences in cognition: the role of testosterone and sexual orientation. *Brain Cogn.* 41, 245–262.
- Neese, S.L., Korol, D.L., Katzenellenbogen, J.A., Schantz, S.L., 2010. Impact of estrogen receptor alpha and beta agonists on delayed alternation in middle-aged rats. *Horm. Behav.* 58, 878–890.
- Nilsen, J., Brinton, R.D., 2002. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. *Endocrinology* 143, 205–212.
- O'Malley, C.A., Hautamaki, R.D., Kelley, M., Meyer, E.M., 1987. Effects of ovariectomy and estradiol benzoate on high affinity choline uptake, ACh synthesis, and release from rat cerebral cortical synaptosomes. *Brain Res.* 403, 389–392.
- Ohkura, T., Isse, K., Akazawa, K., Hamamoto, M., Yaoi, Y., Hagino, N., 1994. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. *Endocrine J.* 41, 361–371.
- Ohkura, T., Isse, K., Akazawa, K., Hamamoto, M., Yaoi, Y., Hagino, N., 1995. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. *Dementia* 6, 99–107.
- Olsen, L., Rasmussen, H.B., Hansen, T., Bagger, Y.Z., Tanko, L.B., Qin, G., Christiansen, C., Werge, T., 2006. Estrogen receptor alpha and risk for cognitive impairment in postmenopausal women. *Psychiatr. Genet.* 16, 85–88.
- Olton, D.S., Becker, J.T., Handelmann, G.E., 1979. Hippocampus, space, and memory. *Behav. Brain Sci.* 2, 313–365.
- Orr, P.T., Lewis, M.C., Frick, K.M., 2009. Dorsal hippocampal progesterone infusions enhance object recognition in young female mice. *Pharmacol. Biochem. Behav.* 93, 177–182.
- Orr, P.T., Rubin, A.J., Fan, L., Kent, B.A., Frick, K.M., 2012. The progesterone-induced enhancement of object recognition memory consolidation involves activation of the extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin (mTOR) pathways in the dorsal hippocampus. *Horm. Behav.* 61, 487–495.
- Osterlund, M.K., Gustafsson, J.A., Keller, E., Hurd, Y.L., 2000. Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERalpha mRNA. *J. Clin. Endocrinol. Metab.* 85, 3840–3846.
- Packard, M.G., Teather, L.A., 1997b. Posttraining estradiol injections enhance memory in ovariectomized rats: cholinergic blockade and synergism. *Neurobiol. Learn. Mem.* 68, 172–188.
- Pappas, C.T., Diamond, M.C., Johnson, R.E., 1979. Morphological changes in the cerebral cortex of rats with altered levels of ovarian hormones. *Behav. Neural Biol.* 26, 298–310.
- Parkes, A.S., Bellerby, C.W., 1926. Studies on the internal secretions of the ovary: I. The distribution in the ovary of the oestrus-producing hormone. *J. Physiol.* 61, 562–575.
- Parkes, A.S., 1927. The Internal Secretions of the Ovary. *Proc. R. Soc. Med.* 20, 1663–1667.
- Pau, C.Y., Pau, K.Y., Spies, H.G., 1998. Putative estrogen receptor beta and alpha mRNA expression in male and female rhesus macaques. *Mol. Cell. Endocrinol.* 146, 59–68.
- Paul, S.M., Purdy, R.H., 1992. Neuroactive steroids. *FASEB J.* 6, 2311–2322.
- Pawluski, J.L., Brummelte, S., Barha, C.K., Crozier, T.M., Galea, L.A., 2009. Effects of steroid hormones on neurogenesis in the hippocampus of the adult female rodent during the estrous cycle, pregnancy, lactation and aging. *Front. Neuroendocrinol.* 30, 343–357.
- Pazol, K., Northcutt, K.V., Patisaul, H.B., Wallen, K., Wilson, M.E., 2009. Progesterone and medroxyprogesterone acetate differentially regulate alpha4 subunit expression of GABA(A) receptors in the CA1 hippocampus of female rats. *Physiol. Behav.* 97, 58–61.
- Penning, T.M., Sharp, R.B., Krieger, N.R., 1985. Purification and properties of 3 alpha-hydroxysteroid dehydrogenase from rat brain cytosol. Inhibition by nonsteroidal anti-inflammatory drugs and progestins. *J. Biol. Chem.* 260, 15266–15272.

- Perlman, W.R., Matsumoto, M., Beltaifa, S., Hyde, T.M., Saunders, R.C., Webster, M.J., Rubinow, D.R., Kleinman, J.E., Weickert, C.S., 2005. Expression of estrogen receptor alpha exon-deleted mRNA variants in the human and non-human primate frontal cortex. *Neuroscience* 134, 81–95.
- Phillips, S.M., Sherwin, B.B., 1992. Effects of estrogen on memory function in surgically menopausal women. *Psychoneuroendocrinology* 17, 485–495.
- Prossnitz, E.R., Sklar, L.A., Oprea, T.I., Arterburn, J.B., 2008. GPR30: a novel therapeutic target in estrogen-related disease. *Trends Pharmacol. Sci.* 29, 116–123.
- Quirion, R., Wilson, A., Rowe, W., Aubert, I., Richard, J., Doods, H., Parent, A., White, N., Meaney, M.J., 1995. Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired. *J. Neurosci* 15, 1455–1462.
- Register, T.C., Shively, C.A., Lewis, C.E., 1998. Expression of estrogen receptor alpha and beta transcripts in female monkey hippocampus and hypothalamus. *Brain Res.* 788, 320–322.
- Resnick, S.M., Maki, P.M., Rapp, S.R., Espeland, M.A., Brunner, R., Coker, L.H., Granek, I.A., Hogan, P., Ockene, J.K., Shumaker, S.A., 2006. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. *J. Clin. Endocrinol. Metab.* 91, 1802–1810.
- Resnick, S.M., Espeland, M.A., Jaramillo, S.A., Hirsch, C., Stefanick, M.L., Murray, A.M., Ockene, J., Davatzikos, C., 2009. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. *Neurology* 72, 135–142.
- Rhodes, M.E., Frye, C.A., 2006. ERbeta-selective SERMs produce mnemonic-enhancing effects in the inhibitory avoidance and water maze tasks. *Neurobiol. Learn. Mem.* 85, 183–191.
- Rissman, E.F., Heck, A.L., Leonard, J.E., Shupnik, M.A., Gustafsson, J.A., 2002. Disruption of estrogen receptor beta gene impairs spatial learning in female mice. *Proc. Natl. Acad. Sci. USA* 99, 3996–4001.
- Rocca, W.A., Bower, J.H., Maraganore, D.M., Ahlsgog, J.E., Grossardt, B.R., de Andrade, M., Melton, L.J., 2007. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. *Neurology* 69, 1074–1083.
- Rodgers, S.P., Bohacek, J., Daniel, J.M., 2010. Transient estradiol exposure during middle age in ovariectomized rats exerts lasting effects on cognitive function and the hippocampus. *Endocrinology* 151, 1194–1203.
- Rodriguez-Sierra, J.F., 1986. Extended organizational effects of estrogen at puberty. *Ann. NY Acad. Sci.* 474, 293–307.
- Rudick, C.N., Woolley, C.S., 2001. Estrogen regulates functional inhibition of hippocampal CA1 pyramidal cells in the adult female rat. *J. Neurosci* 21, 6532–6543.
- Russo, V.E.A., Martienssen, R.A., Riggs, A.D., 1996. Epigenetic mechanisms of gene regulation. Cold Spring Harbor Laboratory Press, Plainview, NY.
- Sandstrom, N.J., Williams, C.L., 2001. Memory retention is modulated by acute estradiol and progesterone replacement. *Behav. Neurosci.* 115, 384–393.
- Savaskan, E., Olivieri, G., Meier, F., Ravid, R., Muller-Spahn, F., 2001. Hippocampal estrogen beta-receptor immunoreactivity is increased in Alzheimer's disease. *Brain Res.* 908, 113–119.
- Savonenko, A.V., Markowska, A.L., 2003. The cognitive effects of ovariectomy and estrogen replacement are modulated by aging. *Neuroscience* 119, 821–830.
- Sherwin, B.B., 1988. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. *Psychoneuroendocrinology* 13, 345–357.
- Sherwin, B.B., 2003. Estrogen and cognitive functioning in women. *Endocr. Rev.* 24, 133–151.
- Sherwin, B.B., 2005. Estrogen and memory in women: how can we reconcile the findings? *Horm. Behav.* 47, 371–375.
- Sherwin, B.B., 2006. Estrogen and cognitive aging in women. *Neuroscience* 138, 1021–1026.
- Sherwin, B.B., Henry, J.F., 2008. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. *Front Neuroendocrinol* 29, 88–113.
- Short, R.A., Bowen, R.L., O'Brien, P.C., Graff-Radford, N.R., 2001. Elevated gonadotropin levels in patients with Alzheimer disease. *Mayo Clin. Proc.* 76, 906–909.
- Shughrue, P.J., Lane, M.V., Merchenthaler, I., 1997. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. *J. Comp. Neurol.* 388, 507–525.
- Shumaker, S.A., Reboussin, B.A., Espeland, M.A., Rapp, S.R., McBee, W.L., Dailey, M., Bowen, D., Terrell, T., Jones, B.N., 1998. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. *Control Clin. Trials* 19, 604–621.
- Shumaker, S.A., Legault, C., Rapp, S.R., Thal, L., Wallace, R.B., Ockene, J.K., Hendrix, S.L., Jones 3rd, B.N., Assaf, A.R., Jackson, R.D., Kotchen, J.M., Wassertheil-Smoller, S., Wactawski-Wende, J., 2003. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA* 289, 2651–2662.
- Shumaker, S.A., Legault, C., Kuller, L., Rapp, S.R., Thal, L., Lane, D.S., Fillit, H., Stefanick, M.L., Hendrix, S.L., Lewis, C.E., Masaki, K., Coker, L.H., 2004. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *JAMA* 291, 2947–2958.
- Silverman, I., Kastuk, D., Choi, J., Phillips, K., 1999. Testosterone levels and spatial ability in men. *Psychoneuroendocrinology* 24, 813–822.
- Simerly, R.B., Chang, C., Muramatsu, M., Swanson, L.W., 1990. Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: an in situ hybridization study. *J. Comp. Neurol.* 294, 76–95.
- Singer, C.A., McMillan, P.J., Dobie, D.J., Dorsa, D.M., 1998. Effects of estrogen replacement on choline acetyltransferase and trkA mRNA expression in the basal forebrain of aged rats. *Brain Res.* 789, 343–346.
- Singh, G.K., Kochanek, K.D., MacDorman, M.F., 1996. Advance report of final mortality statistics, 1994. *Mon. Vital Stat. Rep.* 45, 1–80.
- Singh, M., Meyer, E.M., Millard, W.J., Simpkins, J.W., 1994. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. *Brain Res.* 644, 305–312.
- Sitruk-Ware, R., 2002. Hormonal replacement therapy. *Rev. Endocr. Metab. Disord.* 3, 243–256.
- Smith, D.C., Prentice, R., Thompson, D.J., Herrmann, W.L., 1975. Association of exogenous estrogen and endometrial carcinoma. *N. Engl. J. Med.* 293, 394–401.
- Springer, L.N., McAsey, M.E., Flaws, J.A., Tilly, J.L., Sipes, I.G., Hoyer, P.B., 1996. Involvement of apoptosis in 4-vinylcyclohexene diepoxide-induced ototoxicity in rats. *Toxicol. Appl. Pharmacol.* 139, 394–401.
- Stackman, R.W., Blasberg, M.E., Langan, C.J., Clark, A.S., 1997. Stability of spatial working memory across the estrous cycle of Long-Evans rats. *Neurobiol. Learn. Mem.* 67, 167–171.
- Stewart, J., Kolb, B., 1988. The effects of neonatal gonadectomy and prenatal stress on cortical thickness and asymmetry in rats. *Behav. Neural Biol.* 49, 344–360.
- Talboom, J.S., Williams, B.J., Baxley, E.R., West, S.G., Bimonte-Nelson, H.A., 2008. Higher levels of estradiol replacement

- correlate with better spatial memory in surgically menopausal young and middle-aged rats. *Neurobiol. Learn. Mem.* 90, 155–163.
- Talboom, J.S., Engler-Chiurazzi, E.B., Whiteaker, P., Simard, A.R., Lukas, R., Acosta, J.I., Prokai, L., Bimonte-Nelson, H.A., 2010. A component of Premarin(R) enhances multiple cognitive functions and influences nicotinic receptor expression. *Horm. Behav.* 58, 917–928.
- Tanapat, P., Hastings, N.B., Gould, E., 2005. Ovarian steroids influence cell proliferation in the dentate gyrus of the adult female rat in a dose- and time-dependent manner. *J. Comp. Neurol.* 481, 252–265.
- Thilers, P.P., Macdonald, S.W., Nilsson, L.G., Herlitz, A., 2010. Accelerated postmenopausal cognitive decline is restricted to women with normal BMI: longitudinal evidence from the Betula project. *Psychoneuroendocrinology* 35, 516–524.
- Timaras, P., Quay, W., Vernadakis, A., 1995. *Hormones and Aging*. CRC Press, Boca Raton, NY.
- Toft, D., Gorski, J., 1966. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. *Proc. Natl. Acad. Sci. USA* 55, 1574–1581.
- Tohgi, H., Utsugisawa, K., Yamagata, M., Yoshimura, M., 1995. Effects of age on messenger RNA expression of glucocorticoid, thyroid hormone, androgen, and estrogen receptors in postmortem human hippocampus. *Brain Res.* 700, 245–253.
- Tremblay, G.B., Tremblay, A., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Labrie, F., Giguere, V., 1997. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. *Mol. Endocrinol.* 11, 353–365.
- Tsokas, P., Grace, E.A., Chan, P., Ma, T., Sealfon, S.C., Iyengar, R., Landau, E.M., Blitzer, R.D., 2005. Local protein synthesis mediates a rapid increase in dendritic elongation factor 1A after induction of late long-term potentiation. *J. Neurosci.* 25, 5833–5843.
- Walf, A.A., Frye, C.A., 2008. Conjugated equine estrogen enhances rats' cognitive, anxiety, and social behavior. *Neuroreport* 19, 789–792.
- Wallace, M., Luine, V., Arellanos, A., Frankfurt, M., 2006. Ovariectomized rats show decreased recognition memory and spine density in the hippocampus and prefrontal cortex. *Brain Res.* 1126, 176–182.
- Wallis, C.J., Luttge, W.G., 1980. Influence of estrogen and progesterone on glutamic acid decarboxylase activity in discrete regions of rat brain. *J. Neurochem.* 34, 609–613.
- Wang, J.M., Johnston, P.B., Ball, B.G., Brinton, R.D., 2005. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. *J. Neurosci.* 25, 4706–4718.
- Warren, S.G., Juraska, J.M., 1997. Spatial and nonspatial learning across the rat estrous cycle. *Behav. Neurosci.* 111, 259–266.
- Warren, S.G., Juraska, J.M., 2000. Sex differences and estropausal phase effects on water maze performance in aged rats. *Neurobiol. Learn. Mem.* 74, 229–240.
- Waters, E.M., Yildirim, M., Janssen, W.G., Lou, W.Y., McEwen, B.S., Morrison, J.H., Milner, T.A., 2011. Estrogen and aging affect the synaptic distribution of estrogen receptor beta-immunoreactivity in the CA1 region of female rat hippocampus. *Brain Res.* 1379, 86–97.
- Webber, K.M., Casadesus, G., Bowen, R.L., Perry, G., Smith, M.A., 2007. Evidence for the role of luteinizing hormone in Alzheimer disease. *Endocr. Metab. Immune Disorder. Drug Targets* 7, 300–303.
- Weber, M., Mapstone, M., 2009. Memory complaints and memory performance in the menopausal transition. *Menopause* 16, 694–700.
- Williams, C.L., 1987. Estradiol benzoate facilitates lordosis and ear wiggling of 4- to 6-day-old rats. *Behav. Neurosci.* 101, 718–723.
- Wise, P.M., Ratner, A., 1980. Effect of ovariectomy on plasma LH, FSH, estradiol, and progesterone and medial basal hypothalamic LHRH concentrations old and young rats. *Neuroendocrinology* 30, 15–19.
- Woolley, C.S., Gould, E., Frankfurt, M., McEwen, B.S., 1990. Naturally occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons. *J. Neurosci.* 10, 4035–4039.
- Woolley, C.S., 2000. Effects of oestradiol on hippocampal circuitry. *Novartis Found Symp.* 230, 173–180 discussion 181–7.
- Yaffe, K., Sawaya, G., Lieberburg, I., Grady, D., 1998. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. *JAMA* 279, 688–695.
- Yaffe, K., Lui, L.Y., Grady, D., Stone, K., Morin, P., 2002. Estrogen receptor 1 polymorphisms and risk of cognitive impairment in older women. *Biol. Psychiatry* 51, 677–682.
- Yaffe, K., Lindquist, K., Sen, S., Cauley, J., Ferrell, R., Penninx, B., Harris, T., Li, R., Cummings, S.R., 2009. Estrogen receptor genotype and risk of cognitive impairment in elders: findings from the Health ABC study. *Neurobiol. Aging* 30, 607–614.
- Zhang, W., Lei, Z.M., Rao, C.V., 1999. Immortalized hippocampal cells contain functional luteinizing hormone/human chorionic gonadotropin receptors. *Life Sci.* 65, 2083–2098.
- Zhao, L., Brinton, R.D., 2006. Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease. *BMC Neurosci.* 7, 24.
- Zhao, Z., Fan, L., Frick, K.M., 2010. Epigenetic alterations regulate estradiol-induced enhancement of memory consolidation. *Proc. Natl. Acad. Sci. USA* 107, 5605–5610.
- Zhao, Z., Fan, L., Fortress, A.M., Boulware, M.I., Frick, K.M., 2012. Hippocampal histone acetylation regulates object recognition and the estradiol-induced enhancement of object recognition. *J. Neurosci.* 32, 2344–2351.
- Ziegler, D.R., Gallagher, M., 2005. Spatial memory in middle-aged female rats: Assessment of estrogen replacement after ovariectomy. *Brain Res.* 1052, 163–173.
- Ziel, H.K., Finkle, W.D., 1975. Increased risk of endometrial carcinoma among users of conjugated estrogens. *N. Engl. J. Med.* 293, 1167–1170.